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Sarcopenia: The most conspicuous intractable feature of advancing age is the gradual loss of 
skeletal muscle mass and the resultant loss of strength and mobility, and this is a major driver 
of morbidity and mortality in our ageing population. Loss of muscle is accompanied by loss of 
motoneurons, however what causes the death of motoneurons with advancing age remains 
unknown. Astrocytes are the most numerous and diverse cell type in the central nervous system, 
and play a critical role in neuronal support. Recent research has revealed that in-vitro, ageing 
astrocytes become senescent and express a senescence-associated secretory phenotype (SASP) 
that confers a reduced neuroprotective capacity. However, culturing senescent astrocytes in 
Glial-Derived Neurotrophic Factor (GDNF), a trophic factor critical for survival and 
proliferation of neurons, reversed these effects.  Whether any similar changes occur in vivo is 
unknown, which provides a need for further investigation. 
This study aimed to investigate whether astrocytes in ageing mouse spinal cord become 
senescent, and whether the senescence phenotype can be reversed or attenuated by exercise - a 
known stimulus of GDNF production. The second aim was to investigate whether GDNF levels 
in the lumbar spinal cord reduce with age, and whether any decline is reversed by exercise. To 
inform the aims of this experiment, Semi-Quantitative Immunohistochemistry (SQI) was 
performed on sections of spinal cord from young, elderly, and elderly exercised mice. The 
levels of three proteins of interest were measured: Glial-Fibrillary Acidic Protein (GFAP) an 
intermediate filament protein and marker of astrogliosis; p16, a marker of senescence; and the 
trophic factor GDNF.  
Here we report that levels of GFAP within astrocytes of the lumbar lateral motor column 
showed a trend of increasing with age, although this was not statistically significant (p=0.052). 
Exercise had no effect on GFAP levels. P16-positive cell nuclei were observed in sections of 
both elderly sedentary and elderly exercised, but these did not co-localise with GFAP 
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immunostaining of astrocytes. Instead, p16-positive nuclei appeared to be that of motoneurons, 
a novel finding. GDNF levels showed no change with age, but were increased significantly in 
exercised animals compared to sedentary (p<0.0001), indicating that exercise exerts 
neuroprotective effects by skeletal muscle-derived GDNF production.  
These results indicate that astrocytes become reactive with age and as a result may show 
reduced neuroprotection of motoneurons, contributing to their demise associated with ageing 
and sarcopenia. Although exercise increased GDNF levels within spinal motoneurons, this did 
not correlate with a reduction in astrocyte reactivity or a reduction in the presence of p16-
positive nuclei as hypothesized. Instead, GDNF may exert protective effects for motoneurons 
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1.1 The costly burden of ageing 
We are fortunate enough to live in a 21st century society which has developed to be free of 
most diseases that once killed us in our youth. With the eradication of most infectious diseases 
in developed countries, we are surviving longer into old age, but unfortunately, with ageing 
comes a range of age-associated chronic conditions which we are yet to fully understand. One 
of those age-associated conditions is Sarcopenia. 
Sarcopenia is defined as the deterioration of strength and mobility resulting from loss of muscle 
mass with age. In contrast to other diseases and pathological conditions, every person who lives 
to experience old age will experience the ravages of Sarcopenia, which makes it a high-impact 
area of research.  The ageing population is the only demographic in New Zealand which is 
growing (Fig. 1). The aged 65+ demographic is continually increasing, and is projected to reach  
21–26% by 2043, and 24–33% by 2068 (from 15% in 2016) (National Population Projections., 
2016). The average life expectancy for a New Zealander born in 2015 is 90-95 years, and with 
chronic diseases becoming more prevalent in the aged population, there is an increasing burden 
on the healthcare system and on society (Janssen et al., 2004; Tanimoto et al., 2014; Dennison 
et al., 2017).  
The steady shift in age distribution in New Zealand is increasing the elderly dependency ratio: 
the number of dependents (age 65+) compared to the working population (tax payers) (Fig. 1). 
The projected change in population distribution predicts that by 2036, there will be only 2 tax 
payers for every person aged 65+ - a significant reduction from 7 in the 60’s (National 
Population Projections., 2016). It is therefore critical to take measures to ensure the ever- 
increasing ageing population of New Zealand maintain their functional independence; strength, 




Muscle deterioration leads to increased frailty and subsequent risk of falls and fractures (Waters 
et al., 2010; Tanimoto et al., 2014). The increased incidence of falls and fractures is a large 
contributor to both mortality and morbidity rates among the elderly population (Waters et al., 
2010; Tanimoto et al., 2014); Of older people who fracture their hip, 27% will die within a 
year (Health Quality and Safety Commission New Zealand, 2014). Loss of the ability to live 
independently as a consequence of muscle weakness is costly not only to the individual who 
has lost the capacity to perform everyday tasks, but to society as a whole to support these 
individuals. It was estimated by Janssen et al. in 2004, that the annual cost of healthcare due to 
sarcopenia was US$18 billion in the United States. This expenditure was incurred by nursing 
home admission, hospitalisation and home-based health care (Janssen et al., 2004).  
 
Research into the etiology of Sarcopenia is critical to understanding how interventions may be 
used to attenuate its pathogenesis. Furthering our understanding of the progression of 
Sarcopenia is necessary not only for improving individual quality of life, but to minimise the 
economic and societal impacts of the increasing dependency ratio, which will otherwise become 
a costly burden to following generations.  
Figure 1: New Zealand population demographics and consequences for the dependency 
ratio 
Left: The changing demographic age groups across time from 1948-2068 (projected). Right: The steadily 
increasing age dependency ratio: number of individuals aged 65+ per 100 working individuals (aged 15-64) 




2.1 The pathogenesis of sarcopenia 
The term sarcopenia (In Greek, 'sarx' meaning flesh and ‘penia’ meaning loss) was first 
proposed by Irwin Rosenberg in 1989, but even today, the etiology is not well-understood. 
(Waters et al., 2010). Sarcopenia is the gradual deterioration of muscle mass with ageing. There 
are two ways by which muscle mass can be reduced; a decrease in muscle fiber number, or 
atrophy of individual fibers (Drachman, 1972; Edström et al., 2007) (Fig. 2). These two 
processes are not independent of one another, but occur simultaneously, resulting in reduced 
muscle performance, strength and mobility (Aagaard et al., 2010).  
 
There have been various hypotheses proposing a cause of muscle fiber death or atrophy, the 
predominant being denervation (Rowan et al., 2012). It is well documented that denervation, 
or retraction of the nerve terminal, induces orphaned muscle fibers to undergo disuse atrophy 
(Bongers et al., 2013), yet there remains no complete mechanism underpinning this process. 
Two possible mechanisms for motoneuron terminal retraction (denervation) are the ‘top-down’ 
and the ‘bottom-up’ hypotheses. These hypotheses describe motoneuron dysfunction as a result 
Figure 2: Reduction in muscle fiber number and cross sectional area. 
Left: Data from autopsy studies demonstrates the accelerating reduction in muscle fiber number with age 
(m. quadriceps femoris; data from Lexell et al. (1988).Right: Decrease in muscle cross-sectional area (CSA) 
and infiltration of collagen and fat as a result of ageing (a)(Caserotti et al., 2008). (Aagaard et al., 2010). 
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of either defects at the cell body causing downstream effects at the neuromuscular junction 
(NMJ) (top-down), or conversely, loss of trophic support from skeletal muscle at the NMJ may 
have detrimental consequences to motoneurons in the spinal cord (bottom-up).  
Age-associated denervation not only implicates muscle fibers, but has upstream effects at the 
level of the spinal cord, via loss of skeletal muscle-derived trophic support for motoneurons 
(McCullough et al., 2013). Glial-Derived Neurotrophic Factor (GDNF) is a trophic factor 
produced not only by glia, but also by skeletal muscle where it is then transported in a retrograde 
manner to the cell body of its motoneuron to exert its protective effects (McCullough et al., 
2013) (Fig. 3). Motoneurons depend on GDNF for maintenance and repair, therefore both 
denervation, and the subsequent death of muscle fibers would result in loss of this trophic 
support, and have detrimental consequences for motoneuron survival. An observed reduction 
in motoneuron number with age, particularly within the lumbar enlargement, has been 
documented for both humans and rodents (Tomlinson & Irving, 1977; Rowan et al., 2012). A 
predominant hypothesis suggests the death of motoneurons to precede denervation, and 
consequently muscle fiber atrophy (Sacheck et al., 2007; Rowan et al., 2012). Taking a further 
step back, the question remains; what is it about ageing that causes motoneurons to die? 
 
Figure 3: Schematic representation of skeletal 
muscle-derived GDNF transport. 
Activity-induced, skeletal muscle-derived Glial-Derived 
Neurotrophic Factor (GDNF) is taken up at the Neuro-
Muscular Junction (NMJ) and transported in a retrograde 




2.2 Inflamm-ageing: Age-associated deterioration of the CNS 
Ageing is the primary risk factor for a large majority of chronic diseases, yet the mechanisms 
which drive the ageing process are not well-understood.  Our fundamental lack of understanding 
limits the development of interventions for age-associated diseases such as sarcopenia (Baker 
et al., 2011). Age is associated with multifactorial changes in the metabolic and inflammatory 
status of the central nervous system (CNS) (Liu et al., 2012). Reduced basal metabolic rate, 
chronic low level inflammation characterized by increased circulating cytokines, and 
oxidative stress (quantified by superoxide production, protein oxidation and lipoperoxidation) 
are all hallmarks of ageing (Salminen et al., 2011). A combination of the metabolic and 
inflammatory changes occurring as a result of age may contribute to the complex pathogenesis 
of Sarcopenia. 
It is becoming evident that chronic, low-level inflammation plays a particularly critical role in 
the dysfunction of the neuromuscular system with age (Cruz-Jentoft et al., 2010; Liu et al., 
2012), but what is it about ageing that drives these alterations in the cellular microenvironment? 
A characteristic of ageing tissues is the accumulation of senescent cells, which are thought to 
contribute to the chronic inflammatory environment observed within these tissues and systems 
(Sasaki et al., 2014; Childs et al., 2015). Further investigation of these cells eludes to a cell-
autonomous theory of ageing and age-associated inflammation. 
2.2.1 Senescence: A cell autonomous theory of ageing 
Replicative senescence was unheard of prior to 1961, when Hayflick and Moorehead observed 
that human fibroblasts did not replicate indefinitely in culture (Hayflick & Moorhead, 1961). 
They discovered that human fibroblasts in culture underwent a finite number of divisions before 
a state of senescence was reached. The term senescence has since been broadened to describe 
states of proliferative arrest induced by various stressors (Sharpless & Sherr, 2015). Senescent 
cells remain metabolically active whilst being held in an extremely stable form of cell-cycle 
arrest (Narita et al., 2003). The discovery of replicative senescence overturned the previous 
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understanding that cells in culture could replicate infinitely, provided they were cultured with 
sufficient growth media. This discovery prompted speculation of a potential link between 
senescence and the ageing process - suggesting a ‘cell-autonomous theory of ageing’ (Childs et 
al., 2015).  
As cellular stresses accumulate during ageing, various signalling cascades are triggered, some 
of which drive cells into a state of senescence (Salminen et al., 2011). Senescence is an in-built 
anti-tumour mechanism to prevent the proliferative expansion of damaged cells leading to 
tumour formation (Mombach et al., 2015). There are a number of cumulative and acute cellular 
stresses which can drive cells to cease division and become senescent, including telomere 
erosion, oxidative stress such as lipoperoxidation, proteotoxic stress - for example β-amyloid 
protein aggregates - and oncogene activation (Kuilman et al., 2008; Bhat et al., 2012).   
Replicative senescence is thought to be induced by progressive telomere erosion (Hewitt et al., 
2012). Telomere erosion is a process which occurs progressively with age; with each mitotic 
division a fragment of DNA is lost from the extreme ends of the chromosomes (Narita et al., 
2003). Over time, this telomere erosion becomes significant enough to initiate a permanent 
DNA Damage Response (DDR) which directs the cell toward a fate of senescence (Hewitt et 
al., 2012; Olivieri et al., 2015). Following this initiation, damage sensor ataxia telangiectasia 
mutated (ATM) is recruited to the site of erosion and stabilizes the tumour suppressor p53, 
which upregulates p21 (Childs et al., 2015). It is the cyclin-dependent kinase inhibitors p21 and 
p16 which then inhibit CDK2/4/6 and in turn, disinhibit Retinoblastoma (Rb) activity on E2F 
target genes which are essential for cell cycle progression (Narita et al., 2003). The Rb family 
of proteins recruit histone deacetylases (HDACs) which ultimately repress gene expression at 
their site of action (Narita et al., 2003).  This cascade of events results in cells which are 
irreversibly halted in the G1 phase of the cell cycle (Ohanna et al., 2011; Demaria et al., 2014)  




2.2.2 Senescence Associated Secretory Phenotype 
Senescent cells express a chronic inflammatory phenotype which was first described by Judith 
Campisi as the Senescence Associated Secretory Phenotype (SASP) (Krtolica & Campisi, 
2002). Markers of the SASP include increased senescence-associated (SA)-β-galactosidase 
activity and upregulated p53, p16 and p21 (discussed above) (Bitto et al., 2010). As well as 
intrinsic markers of cell cycle arrest, senescent cells actively secrete a series of pro-
inflammatory cytokines such a TNFα, interleukins such as IL-6, IL-8 and IL-15, matrix 
metalloproteinases (MMPs), reactive oxygen species (ROS) and growth factors (Demaria et al., 
2014; Das & Svendsen, 2015). It is these factors which generate the chronically damaging 
microenvironment within ageing tissues. 
The SASP is induced via a separate pathway to cell-cycle arrest. The transcription factors NF-
kB and C/EBPβ are involved in producing this inflammatory secretory phenotype, with C/EBPβ 
Figure 4: The cascade of events leading to cell cycle arrest. 
Cumulative stresses activate p16 and the DNA-Damage Response (DDR) which then recruits Ataxia-
Telangiectasia Mutated (ATM) and p53 is stabilised. P16 is also directly upregulated following cellular stresses 
and with p21, acts to inhibit cyclin-dependent kinase activity. Rb is disinhibited and can then inhibit E2F target 
genes, leading to permanent cell cycle arrest (Ohanna et al., 2011). 
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being essential for the production of interleukins such as IL-8 (Olivieri et al., 2015).  The 
secretion of such factors exerts paracrine effects to induce senescence in neighbouring cells, 
resulting in an inflammatory microenvironment within whole tissues (Salminen et al., 2012; 
Olivieri et al., 2015). The SASP has an important short-term role for wound healing which was 
demonstrated by generating a p21 and p16 double knockout mouse (Demaria et al., 2014). The 
knockout mouse showed significantly delayed cutaneous wound closure following a dorsal skin 
puncture, demonstrating a transient role of for the SASP in tissue repair following injury 
(Demaria et al., 2014). Despite this transient role, the chronic nature of the inflammatory 
environment generated by senescent cells with ageing is damaging to surrounding cells and 
tissues over a long period of time (Salminen et al., 2011; Das & Svendsen, 2015).  
2.2.3 The SASP as a therapeutic target 
A hallmark of ageing is the accumulation of senescent cells, and the nature of their 
inflammatory phenotype is implicated in various age-associated diseases (Das & Svendsen, 
2015). Due to the damaging nature of the SASP, it is an attractive target for delaying the 
progression of these age-associated diseases and overall tissue degeneration. Therapeutic 
targeting of the NF-kB and C/EBPβ pathways has shown promising results in reversing 
senescence-induced changes in cell morphology and the SASP (Walters et al., 2016).  
The complete removal of p16-positive senescent cells in late-life attenuated the progression of 
various age-associated disorders including sarcopenia (measured by lordokyphosis and muscle 
diameter) (Baker et al., 2011), suggesting a role for cellular senescence in the pathogenesis of 
sarcopenia. The therapeutic benefit of removal of senescent cells was also demonstrated in a 
study which used a Forkhead box protein O4 (FOXO4) peptide to competitively inhibit FOXO4 
activity on p53. Inhibition of FOXO4 induced apoptosis of senescent cells, effectively restoring 
renal function, fitness and fur density in aged mice (Baar et al.). These findings outline the 
detrimental effects of the SASP, and its potential as a therapeutic target to restore homeostasis 
in aged tissues. 
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There is strong evidence that senescence is a potential therapeutic target to reverse the effects 
of cellular ageing. To relate these findings to sarcopenic etiology, we must determine which 
cells involved in the chain of command for motor function are affected by senescence. 
Motoneurons and muscle fibers are the most obvious candidates for understanding degeneration 
of motor function. Nonetheless, by taking a step back one can acknowledge that these cells do 
not function in isolation, but rely on various other support cells for maintenance, repair and 
general function. It is these support cells which must be investigated to put together the story 
of Sarcopenia and neuromuscular ageing. 
2.3 Astrocytes are critical support cells 
Astrocytes are the most numerous cell in the CNS and have several roles in maintaining 
neuronal homeostasis (Bitto et al., 2010; Rodríguez-Arellano et al., 2016) These include 
processing excess neurotransmitter via tripartite synapses (synapses between neurons which 
can be modulated by astrocyte-neuron interaction), ion homeostasis, inflammatory defence, 
antioxidant response and establishment of the blood-brain barrier (Bellaver et al., 2017) (Fig. 
5). Their broad functionality can partly be attributed to their cytoskeletal organization, abundant 
in Glial-Fibrillary Acidic Protein (GFAP), an intermediate filament protein specific to 
astrocytes (Nakagawa & Schwartz, 2004; Souza et al., 2015). Astrocytes are characterized by 
highly ramified processes which extend out to interact with vasculature, neurons and 
neighbouring astrocytes simultaneously (Bushong et al., 2004) (Fig. 5). Due to the diverse 
nature of the role of astrocytes, their demise is implicated in various pathological diseases and 
disorders of the CNS and potentially Sarcopenia. 
2.3.1 Astrocyte senescence and neuroinflammation 
The senescent state and resulting SASP of astrocytes was defined in a study which exposed 
astrocytic cultures to sub-lethal hydrogen peroxide (H2O2) concentrations and analysed 
resulting changes in the transcriptome (Crowe et al., 2016). Astrocytes are particularly sensitive 
11 
 
to low levels of H2O2, making them more susceptible to the cellular stresses that accumulate 
with age (Mombach et al., 2015). Senescent astrocytes express a characteristic SASP, as well 
as an enlarged morphology due to actin reorganization, and increased Glial Fibrillary Acidic 
Protein (GFAP) a well-known marker of astrogliosis and astrocyte reactivity (Salminen et al., 
2011).  
 
The literature regarding astrocytes and the SASP is largely based on diseases of the brain, such 
as Alzheimer’s and Parkinson’s diseases, where their secretory phenotype is shown to 
contribute to the pro-inflammatory status observed (Mombach et al., 2015). The presence of β-
amyloid protein aggregates triggers the senescent pathway in astrocytes, and results in increased 
IL-6 production - a characteristic of the SASP (Bhat et al., 2012). This secretory phenotype is 
what gave Alzheimer’s Disease its term ‘inflamm-aging’ disease - resulting from ageing with 
associated inflammation (Mombach et al., 2015). The disease state of Alzheimer’s implicates 
Figure 5: Schematic of astrocytic roles and interactions in the central nervous system.  
Schematic shows astrocytes taking part in tripartite synapses, interacting with blood vessels to maintain the 
blood brain barrier, processing metabolites and releasing vasoactive substances into the blood. Figure adapted 
from (Maragakis & Rothstein, 2006).(Glu = Glutamate). 
12 
 
the significant role of astrocytes in maintaining the microenvironment of the CNS, and the 
consequences when this role is disrupted (Rodríguez-Arellano et al., 2016).  
A study investigating the changes in astrocytic markers in an AD rodent model saw a reduction 
in GLAST (glutamate-aspartate transporter) immunoreactivity and Glutamine Synthetase (Bitto 
et al., 2010). There was also a significant increase in the presence of ROS, RNA oxidation and 
an age-dependent reduction in Superoxide Dismutase activity (Bellaver et al., 2017). All these 
features indicate an overall reduced ability of astrocytes to process neurotransmitter and 
reactive oxygen species (ROS) in the diseased and senescent state. These findings reiterate the 
diversity in astrocytic function within the CNS, and thus the complex, multifactorial pathology 
associated with astrocytic dysfunction. 
A large proportion of studies which address the role of astrocytes in the spinal cord direct their 
focus on motoneuron diseases such as Amyotrophic Lateral Sclerosis (ALS) and Spinal 
Muscular Atrophy (SMA) (Das & Svendsen, 2015; Zhou et al., 2016). ALS is of particular 
interest in relation to sarcopenia, as it is associated with an accelerated ageing phenotype 
characterised by the accelerated loss of spinal motoneurons (Pirooznia et al., 2014).  
2.3.2 Astrocytes play a role in motoneuron dysfunction: ALS 
Astrocytes have been implicated in various neurodegenerative disorders via their reduced 
neuroprotective capacity in the senescent state, one of which is ALS (Bitto et al., 2010).  
ALS is characterized by exaggerated levels of oxidative stress - a hallmark of normal ageing 
(Das & Svendsen, 2015). Twenty percent of familial ALS cases are characterized by a mutation 
in the SOD1 enzyme, resulting in the rapid progressive loss of both upper and lower 
motoneurons, followed by muscle atrophy and paralysis (Das & Svendsen, 2015). SOD1 is 
responsible for processing and destroying superoxide free radicals in neurons, therefore the 
mutation results in detrimental levels of oxidative stress. Wild-type astrocytes, due to their 
antioxidant capability, show a protective effect on SOD1 mutant motoneurons in the lumbar 
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spinal cords of mice (Das & Svendsen, 2015). Conversely, SOD1 mutant (150 day-old) and 
senescent astrocytes (300 day old) both caused wild-type motoneurons to die (Das & Svendsen, 
2015). This study, published in 2015, is one of the first to demonstrate a link between senescent 
astrocytes and their reduced neuroprotective capacity for motoneurons. No study has yet 
explored the effects of ageing alone on astrocyte neuroprotective capability, and the mechanism 
by which senescence impairs their homeostatic role in health or disease remains unknown (Das 
& Svendsen, 2015).  
As previously discussed, ageing is associated with increased cellular stress (oxidative and 
metabolic stress) (Salminen et al., 2011). It is the multifactorial stresses of ageing that drive 
cells into a state of senescence (Fig. 6). Astrocytes are of particular interest with regard to the 
SASP, as they are sensitive to low levels of free radicals due to their high metabolic rate and 
oxygen consumption (Crowe et al., 2016). This makes them susceptible to the ravages of 
ageing, and thus more likely to enter a state of senescence (García-Matas et al., 2008; Bitto et 
al., 2010). Although astrocytes have antioxidant defence systems such as glutathione, 
glutathione transferase and SOD, these defences are compromised with age (García-Matas et 
al., 2008). Due to the critical functions served by astrocytes in the CNS, disruption of their 
neuroprotective capacity has multiple implications which must be further investigated in 





2.4 Glial-Derived Neurotrophic Factor (GDNF) 
2.4.1 Protective role for motoneurons 
Trophic factors such as Glial-Derived Neurotrophic Factor (GDNF) are required to enhance 
survival and proliferation of neurons (Bellaver et al., 2017). GDNF plays an integral role in 
maintaining the neuromuscular system and promoting neuronal plasticity (Gyorkos et al., 
2014). GDNF is produced by both glial cells and skeletal muscle, where it can be taken up at 
the NMJ and be transported in a retrograde manner to the cell body (Li et al., 2007) (Fig. 3). A 
continuous supply of neurotrophic factors is essential for the maintenance of mature 
motoneurons and repair following injury (Gyorkos et al., 2014).   
GDNF was first discovered in dopaminergic neurons of the midbrain (Lin et al., 1993), but has 
since been identified in Schwann cells, skeletal muscle and motoneuron axons and cell bodies 
Figure 6: Various triggers of senescence and the resulting senescence 
phenotype of astrocytes. 
Schematic representation showing the various stressors which induce astrocytes to become 




(Gyorkos et al., 2014). GDNF acts on target cells via its receptor GFR-alpha which interacts 
with RET tyrosine kinase receptors (Gyorkos et al., 2014). GDNF has protective and 
regenerative roles, therefore an age-dependent reduction within the CNS may contribute to 
various neuropathological conditions (Li et al., 2007; Bellaver et al., 2017). It has been 
proposed that a contributing factor to loss of motoneurons with age is a reduction in 
neurotrophic support from skeletal muscle (McCullough et al., 2013). 
GDNF is the most potent neurotrophic factor associated with motoneuron survival 
(McCullough et al., 2013). Knockout of GDNF protein production or its receptor GFRα1 
resulted in a 24-25% loss in lumbar spinal motoneurons and a reduction in ventral root diameter 
(Gould et al., 2008; McCullough et al., 2013). The role of GDNF has also been established in 
the motoneuron survival of ALS patients. Exogenous delivery of GDNF, or genetic engineering 
of neural progenitors to secrete GDNF substantially improved survival of Superoxide 
Dismutase (SOD1) mutant rats, and showed a protective effect on their motoneurons (Das & 
Svendsen, 2015). These findings provide an insight into the critical role of GDNF in 
motoneuron maintenance and survival, and the therapeutic potential for GDNF in the treatment 
of ALS and the also for motoneuron loss associated with ageing (Das & Svendsen, 2015). 
2.4.2 Skeletal muscle vs astrocyte-derived GDNF 
There are two sources by which motoneurons receive GDNF; astrocyte-derived and skeletal 
muscle-derived (Li et al., 2007). Motoneurons have the capacity to transport GDNF in both an 
anterograde and retrograde directions depending on both the source and site of action required 
- either the cell body or nerve terminal (Ortega-de San Luis & Pascual, 2016). It is for this 
reason the neurotrophic factor was considered as a potential therapy for motoneuron diseases 
such as ALS (Ortega-de San Luis & Pascual, 2016).   
Various studies have looked at the two sources of GDNF in the context of motoneuron survival 
in SOD1-mutant mouse models. One such study cultured astrocytes in medium containing 
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exogenous GDNF for 7 days. GDNF completely reversed the increase in p21 in aged astrocytes, 
as well as IL-6 and IL-8, two pro-inflammatory markers of the SASP (Das & Svendsen, 2015). 
This study also demonstrated that short-term priming of aged astrocytes in GDNF increases 
their neuroprotective capacity, with motoneurons showing increased survival following culture 
with GDNF-primed astrocytes (Das & Svendsen, 2015). Whether this effect leads to a reduction 
in other damaging factors of the SASP or stimulates production of protective factors is yet to 
be investigated, in both ageing and disease.  
While astrocyte-derived GDNF can act directly on the motoneuron cell body, skeletal muscle-
derived GDNF is transported along the axon in a retrograde manner to exert its effects at the 
cell body (McCullough et al., 2013). A study by Liu et al. (2012) used a transgenic approach 
to overexpress GDNF in either skeletal muscle (Myo-GDNF) or in astrocytes (GFAP-GDNF). 
They measured motoneuron survival, disease-onset, muscle innervation, axonal degeneration 
and locomotor performance (Liu et al., 2012). In contrast to the previous study, GFAP-GDNF 
overexpression showed no neuroprotective effects in SOD1-mutant mice, but Myo-GDNF 
resulted in improvement of all parameters (Li et al., 2007). These findings suggest that skeletal 
muscle-derived GDNF exerts potent effects on motoneurons as well as acting on astrocytes to 
increase their neuroprotective capacity, proposing a mechanism for exercise to have 
neuroprotective benefits. 
2.4.3 GDNF can modulate astrocytes 
Not only do astrocytes produce endogenous GDNF, but they retain the receptors, GFR-alpha 
and RET during ageing, therefore maintain the ability to be modulated by GDNF (Das & 
Svendsen, 2015). This means any detrimental effects of reduced GDNF signalling via astrocytes 
may be reversible via an exogenous source of GDNF - such as skeletal muscle-derived 




GDNF expression is increased in the L1-L3 region of the spinal cord following exercise, and 
causes axonal branching and a subsequent increase in motor unit size (McCullough et al., 2013). 
The benefits for increased GDNF within motoneurons are direct, but it remains to be seen 
whether skeletal muscle-derived GDNF can act on astrocytes via their receptors GFR-alpha and 
RET, subsequently increasing their neuroprotective ability. Exogenous GDNF was able to 
reduce the SASP and accordingly, restore the neuroprotective capacity of astrocytes in culture 
(Das & Svendsen, 2015). These findings support the hypothesis that exercise may have 
protective effects on astrocytes via activity-dependent, skeletal muscle-derived GDNF, but the 
mechanism by which this may occur in vivo remain unknown. 
There is extensive research into the therapeutic benefits of GDNF for neurodegenerative 
conditions, yet the mode of action on neuronal circuits is poorly characterized (Ortega-de San 
Luis & Pascual, 2016). How the role of GDNF is impeded with age and whether this disruption 
is via an indirect mechanism through astrocytes remains unknown. GDNF reduced markers of 
the SASP in culture (Das & Svendsen, 2015), but it is yet to be investigated whether this occurs 
Figure 7: Schematic demonstrating the two sources of 
GDNF and their modes of action on motoneurons. 
Enlarged representation of astrocytic Glial-Derived Neurotrophic Factor 
(GDNF) receptors GFR-alpha and RET. 
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in vivo. It also remains unknown whether exercise plays a role in restoring astrocyte vitality and 
neuroprotective capacity via GDNF activity, or an alternative mechanism in the spinal cord.  
2.5 Exercise as an intervention for neuromuscular deterioration 
2.5.1 Exercise reduces the senescence phenotype 
Due to the nature of the cellular stresses which induce cellular senescence, it can be 
hypothesized that premature cellular senescence may be attenuated by reducing metabolic 
dysfunction. It is well-established that physical activity provides many benefits on the 
metabolic status of the body and reduces the risk of numerous age-related diseases (Schafer et 
al., 2016). The molecular mechanisms by which exercise attenuates these age-related 
physiological changes are poorly characterized, specifically how exercise may attenuate 
senescence.  
In terms of astrocyte senescence, it is known that senescent astrocytes display an enlarged, 
hypertrophied morphology characterised by increased GFAP expression: a hallmark of the 
ageing brain (Diana et al., 2010; Latimer et al., 2011). It was demonstrated that aerobic exercise 
reduced astrocyte hypertrophy in the hippocampus of middle-aged mice (Latimer et al., 2011). 
This reduction in hypertrophy was accompanied by improved vascular function measured by 
vascular corrosion casting visualised under a scanning electron microscope (Latimer et al., 
2011). Astrocytes play an integral role in vascular function and neurovascular coupling, 
therefore these findings demonstrate that exercise may exert indirect protective effects for the 
CNS by improving astrocytic function (Latimer et al., 2011). 
Exercise has been shown to reduce triggers of cellular senescence, preventing the pathway 
altogether. (Soares et al., 2015) conducted a study in 2015 which evaluated the effects of a 
combined exercise protocol (strength and aerobic training) on DNA damage and oxidative 
stress, measured by lipoperoxidation in human lymphocytes. Both parameters were 
significantly reduced following 16 weeks of exercise, and this was supported by a significant 
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increase antioxidant capacity, measured by ABTS radical-scavenging activity (Soares et al., 
2015). This data suggests a role for exercise in reducing oxidative stress - a well-established 
trigger for the senescent pathway (Bitto et al., 2010; Das & Svendsen, 2015). As well as 
oxidative stress, telomere erosion is a well-understood trigger for cellular senescence, and long 
term vigorous exercise was shown to conserve telomere length in older athletes (Werner et al., 
2009). These findings demonstrate the potential mechanisms by which exercise may reduce the 
observed accumulation of senescent cells with ageing, and therefore the senescence-induced 
inflammatory microenvironment of aged tissues. 
2.5.2 Exercise increases neurotrophin production 
Exercise not only has a role in reducing markers of cellular senescence and improving astrocyte 
functionality, but also results in increased production of  GDNF, BDNF, IGF and NT4 
(Funakoshi et al., 1995; Park & Höke, 2014). Protein levels in both skeletal muscle and serum 
were significantly increased following exercise (Park & Höke, 2014). The proposed explanation 
for the observed increase of trophic factors in the distal nerves of exercised mice is not only the 
changes in serum level, but also increased blood flow to the region which occurs as a result of 
increased exertion (Park & Höke, 2014). Exercise is known to increase vascularization of 
muscle tissue, which could in-turn improve supply of trophic factors to their sites of action, 
including Schwann cells of peripheral nerves (Park & Höke, 2014). Most importantly, it is 
skeletal muscle-derived GDNF which has been shown to increase with exercise and exert the 
most potent effects on motoneuron survival (Li et al., 2007; McCullough et al., 2013; Park & 
Höke, 2014). 
GDNF protein levels measured by an Enzyme-linked Immunosorbent Assay (ELISA) were 
increased significantly in the lumbar region of the spinal cords of exercised mice (McCullough 
et al., 2013). A significant increase in spinal GDNF was observed in both 6 month old and 24 
month old exercised mice, demonstrating that exercise can increase trophic levels, even into 
old age (McCullough et al., 2013). Increased GDNF protein content was correlated with 
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motoneurons double the size of those in the sedentary controls (McCullough et al., 2013). It 
can be interpreted from these results that exercise results in increased skeletal muscle-derived 
GDNF which is transported in a retrograde manner to exert effects at the motor end plate and 
the motoneuron cell body (Li et al., 2007; Gyorkos et al., 2014; Park & Höke, 2014) (Fig. 7).   
2.6 Astrocytes, GDNF and the SASP 
Understanding the fundamental processes causing astrocytic dysfunction associated with 
ageing, is integral to finding therapeutic strategies to target motoneuron dysfunction associated 
with both ageing and disease. Reduced neuroprotective capacity of astrocytes in the senescent 
state was recently been demonstrated in a study by Das & Svendsen (2014). The use of SOD1 
mutant animals proved to be effective at demonstrating the functional alterations of senescent 
astrocytes due to the similarities observed in the molecular profile of aged wild-type (300-day 
old) and end-stage (150-day old) SOD1 mutants (Das & Svendsen, 2015).  Both of these animal 
models showed a reduced protective capacity of motoneurons which was restored following 
culture in GDNF. 
The literature regarding astrocyte senescence and their neuroprotective capacity in the 
senescent state remains limited in the context of normal ageing. The literature is also largely 
based on astrocytes in culture, which may not be directly translatable to in vivo conditions. 
There remains to be established a complete mechanism by which astrocyte senescence affects 
motoneurons, and furthermore, how skeletal muscle-derived GDNF may act on astrocytes to 
restore their neuroprotective capacity.  
Das and Svendsen are the only authors thus far who have shown a link between senescent 
astrocytes, GDNF and motoneuron viability. They demonstrate the ability of GDNF to directly 
reduce components of the SASP, but it remains to be seen whether this effect can occur in-vivo. 
The significance of understanding these mechanisms lies in understanding sarcopenic etiology. 
Astrocyte dysfunction and resulting motoneuron death may be contributing to muscle wastage 
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with age, via denervation of muscle fibers inducing disuse atrophy and overall reduced muscle 
mass (section 2.1). The protective effects of GDNF may for both motoneurons and astrocytes 
may prove to be useful in counteracting age-associated frailty and sarcopenia. The current 
literature provides a need for further investigation on how GDNF may exert its effects in-vivo, 




Figure 8: Schematic representation of the proposed interactions between skeletal-
muscle derived GDNF, motoneurons and astrocytes. 
This schematic shows the proposed relationship between skeletal muscle-derived GDNF which is taken 
up at the Neuromuscular Junction (NMJ), transported in a retrograde manner and exerts effects at the 
motoneuron cell body, as well as acting on astrocytes to reduce their reactive phenotype. 
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 Aims and hypotheses 
Aim one: To determine whether astrocytes in the lateral lumbar column of mice become 
senescent or reactive with age, and whether this is reversed or attenuated by exercise. 
Hypothesis: I hypothesize that the abundance of both p16 and GFAP within astrocytes of the 
lateral lumbar column will increase with age, and exercise will attenuate or reverse this increase. 
Aim two: Determine if the amount of GDNF in motoneurons of the lateral lumbar column 
reduces with age, and whether exercise can reverse or attenuate this reduction. 
Hypothesis: I hypothesize that the amount of GDNF will be reduced within motoneurons of the 
lateral lumbar column with age, and this will be reversed or attenuated with exercise. 
Aim three: To determine if there is a correlation between changes in amount of GFAP and p16 
expression and changes in amount of GDNF in the lateral lumbar column with age. 
Hypothesis: I hypothesise that with age, there will be an increase in p16 expression and a 
subsequent reduction in GDNF within the same cells. I also hypothesise that with exercise, 
















The first aim of this experiment was to determine whether astrocytes in the lateral lumbar 
enlargement of the spinal cord become senescent with age, and show signs of astrogliosis. The 
second aim was to find out whether exercise could reverse or attenuate these effects by 
increasing levels of the trophic factor, GDNF. To inform the aims of this experiment, I used 
semi-quantitative immunohistochemistry (SQI) to fluorescently label the proteins of interest on 
sections of mouse spinal cord, and use staining intensity as an indicator of relative protein 
amount.  
A total of 15 female C57B6 mice were used; 5 young animals (6 weeks), 5 elderly sedentary 
(24 months) and 5 elderly exercised mice (24 months with exposure to a running wheel for the 
final 4 months of life). Goat anti-Glial-Fibrillary Acidic Protein (GFAP) was used to mark 
astrocytes and indicate astrogliosis, rabbit anti-p16Ink4a was used as a marker of senescence 
and cell-cycle arrest, and sheep anti-Glial-Derived Neurotrophic (GDNF) factor was used to 
label GDNF. GDNF was co-stained with Choline-Acetyltransferase (ChAT), a specific marker 
of spinal motoneurons, to allow measurement of GDNF within motoneurons specifically. All 
proteins of interest proteins were labelled with Alexa Fluor® conjugated secondary antibodies.  
Western blotting was used to attempt to measure relative amounts of p16 protein levels in young 
and elderly sedentary mouse spinal cord tissue. 
4.2 Ethics 
Ethical consent for the experiments documented in this thesis was obtained from the University 




The data obtained was derived from female C57B6 mice sourced from the University of Otago 
breeding colony at the Hercus Taieri Resource Unit. This strain was chosen as it shows several 
age-related musculoskeletal changes (reduction in muscle mass, force generating capacity and 
reduction in myofiber number) that are similar to those observed in humans, in both degree and 
relative age of onset (Ballak et al., 2014). For this study, mice were compared by both age and 
activity level; young (1-3 months old), elderly sedentary (24 months old) and elderly exercised 
(24 months old with exposure to a running wheel for the final 4 months of life). The young and 
elderly groups are equivalent to approximately 15 and 70 years old respectively (The Jackson 
Laboratory, 2017). A total of 5 animals per group (listed above) were used for data collection. 
Animals were group housed to minimize levels of stress, with the exception of the elderly 
exercised mice. The exercise protocol involved exposure to a running wheel fitted with a device 
to track the distance each mouse run per day. The cages for these animals were designed to 
prevent climbing, ensuring the only exercise undertaken was on the running wheel. For the 
duration of the exercise protocol, the solitary housed animals were caged near to one another to 
allow verbal communication and smell, both shown to reduce stress (National Research 
Council, 2008). Mice had access to food (standard chow) and water ad libitum, as well as 
enrichment toys. The mice were housed with a 12:12 hour light/dark cycle.  
4.4 Anesthesia and transcardial perfusion 
Animals were euthanized with an intra-peritoneal (IP) injection of sodium pentobarbital at a 
dilution of 15mg/ml. The toe-pinch reflex was used to determine deep anesthesia prior to 
beginning surgery. Following loss of the toe-pinch reflex, the mouse was taped down with its 
hind limbs and forelimbs spread to expose the anterior torso. An incision was made in the 
inferior abdomen along the midline, and the skin was cut in the rostral direction, ensuring the 
abdomen wall remained intact. The skin was peeled back to expose the ribcage, and two cuts 
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were made lateral to the sternum in a V-shape. The ribcage was then deflected to expose the 
mediastinum and the right atrium was cut to allow venous blood to drain out. The left ventricle 
was perfused with a 23 gauge needle, injecting heparinised phosphate buffered saline at 37°C, 
at a rate of 6ml/min using a peristaltic pump. Heparin prevents blood clot formation during 
perfusion. Next, the fixative (1% paraformaldehyde in 0.1M phosphate-buffered saline), also at 
37°C, was perfused for 5 minutes and the rate of perfusion was gradually increased to 10ml/min 
in a step-wise manner. (Appendix C). 
4.5 Spinal cord dissection 
The animals were skinned and eviscerated prior to the tissues of interest being removed. The 
animals were decapitated below the brainstem to expose the spinal cord. The vertebral column 
was dissected ventrally, by cutting one single vertebra at a time and deflecting it backwards to 
gradually expose the cord. The cauda equina was severed, and the cord was gradually lifted 
with forceps, severing the dorsal and ventral roots to gradually release it. (Appendix C).  
4.6 Techniques to reduce Freezing Artifact  
The spinal cord was stored in a 20% sucrose/TBS solution for a minimum of 24 hours prior to 
freezing for cryoprotection. The cord was cut to isolate the lumbar enlargement and the tissue 
was blotted dry and transferred to a 1:1 solution of 20% sucrose and OCT overnight. This was 
found to prevent the cord from separating from the OCT in the freezer or during sectioning. 
The cord was embedded in OCT in small, hand-made foil capsules. The foil capsules were 
partially submerged in isopentane which had been cooled to -170°C with liquid nitrogen. Partial 
immersion is essential to allow for expansion and prevent cracking as the OCT freezes. 
Isopentane is used for freezing as it has a higher boiling point than nitrogen, and does not 
vaporize upon contact with the foil capsule. The use of isopentane allows for a freezing time of 




Tissue was sectioned transversely using an upright Leica CM1850 cryostat at -22°C. The tissue 
was mounted onto a tissue mounting stud using OCT, and then sectioned at 16μm and picked 
up onto slides treated with poly-L-lysine (Sigma-Aldrich, AKL, NZ). Poly-L-lysine is 
polycationic in nature, and interacts with anionic sites in the tissue sections, adhering them to 
the slide (Huang et al., 1983). The slides were left to dry for approximately 30 minutes prior to 
being stored in the -80°C freezer until required. 
Sectioning was performed systematically to allow each protein of interest to be assessed 
regularly along the entire length of the lumbar enlargement (Fig. 9). For each spinal cord, 
sections were cut in sets of 10 slides beginning at the rostral end of the enlargement. One section 
was cut per slide, for 10 slides, and this was repeated until each slide had 10 sections. The next 
1.6mm of the cord was sectioned and used for spare slides, and this method was repeated for 
the middle and caudal regions of the lumbar enlargement. 
 
 
Figure 9: Sectioning schematic 
The systematic method used to section along the entire length of the lumbar enlargement and 
acquire sections from the rostral, middle and caudal regions.* Indicates slides used for other 
experiments not a part of this project. 
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4.8 Semi-Quantitative Immunohistochemistry 
The use of semi-quantitative immunohistochemistry (SQI) allows intensity of a stained tissue 
specimen to be used as an arbitrary indicator of protein content within a sample. It is assumed 
that as protein content increases, this will be reflected in an increase in fluorescence intensity 
of the staining. SQI relies on the assumption that variables which may affect immunostaining 
intensity such as primary antibody concentration, temperature and incubation time have equal 
impact on comparable samples. This method has been tested in the Sheard Laboratory through 
the development of a reference standard containing a known amount of the protein of interest. 
The reference standard was then stained alongside the tissue of interest and used to demonstrate 
the linear relationship between protein amount and brightness of staining.  
For a standard to be reliably comparable to the tissue specimens, it must be equally affected by 
variables known to affect staining of tissue samples, including protein amount and antibody 
concentration. To validate the standard, sequential dilutions of the protein of interest were 
suspended in agarose gel and sectioned on a vibratome. The sections were then mounted onto 
microscope slides alongside sections of the tissue samples. The standards were treated with 
primary and secondary antibodies under identical conditions as the tissue samples and viewed 
under a fluorescence microscope. The fluorescence intensity of the standards was proportional 
to amount of protein present (Appendix D) (Brady, 2015). Next, a single known amount of 
protein was suspended in the agarose gel, and the concentration of primary antibody was varied 
(1:100, 1:300 and 1:900). The resulting staining intensity was proportional to the antibody 
concentration (Brady, 2015) (Appendix D). These results indicate that staining intensity may 
be used as an indicator of protein content, as long as the tissue specimens to be compared are 
treated under identical conditions. 
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4.9 Protocol optimisation 
Immunohistochemistry (IHC) was used to stain the four proteins of interest in this experiment. 
The primary antibodies used were rabbit polyclonal anti-p16INK4a, goat polyclonal anti-
GFAP, sheep polyclonal GDNF and rabbit anti-Choline Acetyltransferase (ChAT) (Table 1). 
The three secondary antibodies used were donkey anti-goat (Alexa Fluor® 405 or 488), goat 
anti-rabbit (Alexa Fluor® 568), and donkey anti-sheep (Alexa Fluor® 488) (Table 1). All 
antibodies used in this study were diluted using an immunodiluent which has been optimised 
in the Sheard lab to give the highest quality immunofluorescent staining (appendix A). Each 
antibody was optimised by performing serial dilutions of 1:50, 1:100, 1:200, 1:400 and 1:800, 
and selecting the dilution which produced the optimal signal: noise ratio. For this optimisation, 
sections were processed together under identical conditions so the only variable was antibody 
dilution. 
For some proteins of interest, antigen retrieval is required to expose the antibody binding site 
which becomes obstructed during fixation. There are multiple methods for antigen retrieval, but 
for this experiment three methods were trialled: sodium dodecyl sulphate (SDS), Heat-Induced 
Epitope Retrieval (HIER) with citrate buffer (pH 6) and HIER with tris buffer (pH 10) 
(appendix A). The HIER protocol involved heating the buffer to 90°C, then fully submerging 
the slides and maintaining a temperature between 80-90°C for 20 minutes. The buffer was then 
left to cool gradually until the temperature was below 40°C, at which point the slides were 
washed three times for five minutes in 1x TBS before primary antibody incubation. 
For the experiments listed below, all slides were submerged in a glycine solution (appendix A) 
following rehydration, to quench any excess aldehyde from the fixation. All antibodies were 
washed off as follows: 3x5 minutes in 1xTBS, 3x5 minutes in 2xTBS and finally 3x5 minutes 
in 1xTBS (appendix A). Prior to mounting, all sections were treated with TrueBlack™ 
autofluorescence quencher (Biotium, CA, USA) diluted 1:20 in 70% ethanol, to reduce 
30 
 
visibility of lipofuscin autofluorescence common in aged tissues. Slides were mounted with 
glycerol/TBS mounting medium with DAPI to stain nuclei (appendix A). 





Conjugate Antibody specificity Catalogue 
number 
Dilution 
p16INK4a Rabbit N/A This antibody is against 
CDKN2A/p16INK4a (aa50-150) and 
recognises mouse and human 
antigen. It has been validated for 
western blot, IHC (fixed and 







GDNF Sheep N/A This antibody reacts with GDNF in 
its mature form and pro-form, so 
multiple bands may be observed in 
western blot. Both forms have 
been shown to be present in 





GFAP Goat N/A This antibody binds to GFAP aa 
417-430 (C terminal cysteine 
residue). Western blot data from 
the supplier of mouse brain lysate 




ChAT Rabbit N/A Antibody against Choline 
Acetyltransferase (ChAT). 
Validated for use in IHC for frozen 




Rabbit Goat AlexaFluor® 568   1:500 
Sheep Donkey Alexa Fluor® 488 Cross-Adsorbed secondary 
antibody reacts with heavy and 









Donkey Alexa Fluor® 488   1:500 
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4.10 Glial Fibrillary Acidic Protein 
Glial Fibrillary Acidic Protein (GFAP) is an intermediate filament protein specific to astrocytes 
(Nakagawa & Schwartz, 2004; Khakh & Sofroniew, 2015), it is the most widely used astrocytic 
marker.  
The optimum dilution of the primary antibody, goat anti-GFAP, was determined to be 1:200 
based on optimal signal: noise ratio. Incubation times were optimised to overnight at 4°C for 
the primary antibody, and 3 hours at room temperature for the secondary antibody. Sections 
were cut at serial thicknesses: 6, 8, 10, 12 and 16μm and optimised at 16μm. Although thinner 
sections result in lower background due to more area outside of the focal plane, astrocytic 
processes are extensive and a single cell may span 40μm in its entirety (Cirillo et al., 2012), 
therefore 16μm allowed for distinction of single astrocytes and their associated processes. 
A solution (appendix A) containing glycine, which quenches any residual paraformaldehyde, 
and two permeabilising agents: tween-20 and triton, was found to improve quality of staining 
of the extensive astrocytic projections. Slides were incubated in this solution for 4 mins, 
followed by 2x5 minute washes in 1xTBS prior to primary antibody incubation. 
4.11 P16  
4.11.1  Immunohistochemistry 
The primary antibody, rabbit anti-p16Ink4a, was run under standard conditions at serial 
dilutions of 1:50, 1:100, 1:200, 1:400 and 1:800, as well as the various permutations of antigen 
retrieval listed in section 1.8. The signal was optimal in tissue processed without antigen 
retrieval at a dilution of 1:200. Incubation time was optimised to overnight at 4°C for the 
primary antibody, and 4 hours at room temperature for the secondary antibody, goat anti-rabbit 
Alexa Fluor® 568. 
To validate the positive signal attained in the spinal cord, sections of positive control tissue 
(paraffin embedded mouse lung carcinoma tissue) known to express high amounts of p16 
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(Witkiewicz et al., 2011) were acquired from the Department of Pathology, University of 
Otago. Prior to staining, the control sections were de-paraffinised by immersion in xylene for 
two minutes, three times. The slides were then transferred to 100% ethanol for two minutes, 
twice, then 95% ethanol for one minute, 70% ethanol for one minute, and finally distilled water 
for two minutes. The sections were run with anti-p16Ink4a at a 1:200 dilution under standard 
conditions, with SDS treatment and HIER with citrate buffer (pH 6) and tris buffer (pH 10). A 
signal was acquired following HIER with tris buffer (pH 10). 
To establish whether p16 is located in nuclei of either astrocytes or motoneurons, p16 was co-
stained with antibodies to both GFAP to label astrocytes, and ChAT to label motoneurons. 
Negative control slides had both primary antibodies omitted. The slides were all run the 
optimised staining protocol as described above. The anti-GFAP protocol was run as described in 
section 1.9. Prior to the anti-ChAT primary incubation, the slides were incubated with goat anti-
rabbit F(ab’)2 fragment (Jackson ImmunoResearch Laboratories Inc., PA, USA), as this primary 
antibody was also raised in rabbit. Rabbit anti-ChAT (1:400) was incubated overnight at 4°C, 
and then the secondary, goat anti-rabbit Alexa Fluor® 488 was incubated for 4 hours at room 
temperature. All slides were washed, treated with TrueBlack™ (Biotium, CA, USA) and mounted 
as described in section 1.8. 
4.11.2  Western blotting 
Western blotting is used to separate out proteins based on molecular weight and then label 
proteins of interest with antibodies to detect them on a membrane. For this experiment, western 
blotting was used to attempt to measure the fold change in amount of p16 in young versus 
elderly spinal cord homogenate. The protocol for western blotting is described below, and the 
optimisation procedure can be found in appendix E. 
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4.11.2.1 Tissue preparation 
Spinal cords removed from euthanised animals (section 1.4) were placed in cold 1x TBS and 
kept on ice. The cord was then cut to remove the lumbar enlargement which was post-fixed in 
1% paraformaldehyde overnight. The rest of the cord was cut into small pieces and placed in a 
1.5ml Eppendorf tube maintained on ice. An equal amount of 0.9-2mm RNAse-free, stainless 
steel beads (Lab Supply, NZ) were added to the tube, followed by 400ul of  
Radioimmunoprecipitation Assay (RIPA) buffer (appendix B) resulting in a 1:1:2 ratio of 
beads, tissue and buffer. The tissue was then homogenised in the bullet blender® (Next Advance 
Storm 24) for 4 minutes on level 10. The homogenate was centrifuged for 15 mins at 15000rcf, 
at 4°C, and the supernatant was removed and put in a separate tube on ice. 
4.11.2.2 Tissue sample analysis 
The protein amount in each sample was calculated to ensure an equal amount of protein was 
loaded into each well of the gel. Protein amount was initially determined using a μDrop™ plate 
(ThermoFisher Scientific, MA, USA), and measuring absorbance with SkanIt software version 
4.1 (ThermoFisher Scientific, MA, USA). First, 1µl of RIPA buffer was added to each ‘blank’ 
plate, this is the standard which will be subtracted from the total absorbance reading. The 
supernatant was vortexed to ensure protein was equally dispersed in the tube, then 1µl of the 
sample was added to each of the two plates in the second row. Absorbance was measured using 
a wavelength of 280nm and subtracting the absorbance readings of the RIPA buffer alone 
(blanks). The Beer-Lambert Law is the linear relationship between concentration and 
absorbance of a substance. A simple equation of absorbance (A) multiplied by path-length of 
light (l) gives protein concentration in mg/ml (µg/µl) (C): 
𝐶 = 𝐴 𝑥 𝑙 
Due to the large variance observed using the μDrop™ Plate technique, a BSA Protein Assay was 
performed to generate a standard curve of absorbance and calculate protein amount of each 
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sample based on individual absorbance readings. 5μl of 8 serial amounts of BSA were added to 
the first 8 wells of a 96-well plate. The next 10 wells were loaded with 5μl of each of the 10 
tissue samples. 1mL of reagent A (DC™ Protein Assay, BioRad, NZ) and 20μl of reagent S 
was then added to the wells. 200μl of reagent B was added to the wells last, and the plate was 
left on an agitating table for 15 mins before being read using the microplate reader. The standard 
curve was generated and protein amount in each sample was determined. The samples were 
aliquoted out into appropriate amounts required for blots, and snap frozen in liquid nitrogen 
before being stored in the -80°C freezer. 
4.11.2.3 Gel electrophoresis 
Sodium Dodecyl Sulphate Poly-Acrylamide Gel Electrophoresis (SDS-PAGE) was used to 
separate proteins based on their molecular weights. The result is bands of protein at various 
levels down the gel which can then be visualised using antibodies. Gel electrophoresis utilises 
the principle that opposites attract, i.e. negatively charged proteins move toward a positively 
charged region of an electrical field. For an SDS-PAGE gel, the negative charge on the proteins 
is acquired from the SDS; this causes them to migrate from the negatively charged cathode to 
the positively charged anode. Large proteins take longer to move through the gel, and 
consequently the end result is a protein ladder with large proteins closer to the cathode, and 
small proteins nearest the anode. A marker ladder composed of dyed proteins of known 
molecular weight was used to indicate molecular weight of the bands formed by the sample. 
The percentage of acrylamide used in the resolving gel is important to consider. Acrylamide is 
the component of the gel which polymerises and forms a matrix which acts like a sieve in 
separating the proteins based on their molecular weights. A high percentage gel forms a denser 
matrix and thus is more effective at separating small proteins, and a low percentage gel contains 
a less-dense matrix of polyacrylamide, and thus small proteins move rapidly through the gel 
and out the other side, leaving large proteins separated out along the gel. For this study a 15% 
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gel was used (table 2) which was appropriate for visualising my protein of interest which is 
16kDa. 
The resolving gel was made by adding all of the reagents to a beaker with a magnetic spinner. 
The TEMED and acrylamide are added last as they initiate setting of the gel. 9ml of resolving 
gel was pipetted into the cassette, followed by a small volume of methanol which smooths the 
surface of the gel and prevents evaporation. The gel was left to set for an hour at room 
temperature. Once set, the methanol was washed off with dH2O, and 3mL of stacking gel (table 
2) was pipetted on top of the resolving gel. A comb was inserted on top (Fig. 10) and this was 
left to set for an hour before the comb was removed and the wells rinsed with distilled water. 
Table 2:  Ingredients for gels for running an SDS-PAGE gel electrophoresis. 
 
The set gel was put into a running frame inside a gel tank filled with running buffer (Appendix 
B). 4μl of the protein ladder (Precision Plus Protein™, BioRad, NZ) was loaded into the first 
well, followed by the first five samples. An initial gel was run with serial protein amounts: 10, 
20, 40 and 80μg, and optimised at 20μg. 20μl was loaded into each well, containing 1μg/μl of 
protein (appendix B); by keeping the amount of protein the same within each well, this ensures 
the samples are directly comparable with respect to the loading control,  
β-actin. The gels were run at 100V for 120 minutes which allowed the proteins to separate out 
completely. 
 Resolving Gel (15%) Stacking Gel (4%) 
dH2O (mL) 3.7 4.766 
Lower Tris (pH 8.8) (mL) 4 - 
Upper Tris (pH 6.8) (mL) - 2 
10% SDS (μl) 160 80 
30% AA:MBA(mL) 8 1.066 
10% Ammonium persulfate (μl) 160 80 
TEMED (μl) 16 8 
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4.11.2.4 Protein transfer to membrane 
Proteins from the gel were transferred onto a polyvinylidene difluoride (PVDF) membrane for 
detection with antibodies. The PVDF membrane was cut to size and soaked in methanol for 1 
minute to activate it, and then washed in transfer buffer for 3 minutes. As the stack was 
assembled (Fig. 10), transfer buffer was poured over the layers, and a small roller was used 
following the addition of each layer to roll out any bubbles which could disrupt the electrical 
current and quality of transfer.  
The transfer sandwich was placed in a transfer cassette and clamped shut. The cassette was 
placed in the transfer box and the box was filled with cold transfer buffer. A magnetic stirrer 
was placed at the bottom of the tank and ice packs were placed inside the tank to keep the buffer 
cold. The whole tank was placed in a box packed with ice and the transfer was run at 100V for 
100 minutes. As the electricity flows between the electrodes, the negatively charged proteins 
move from the gel to the membrane where they can be detected with antibodies. Prior to protein 
detection with antibodies, the PVDF membrane was submerged in Ponceau S red, which stains 
all protein on the membrane to ensure the transfer was successful before continuing. The 
Ponceau S stain was washed off thoroughly in TBST until all the pink was removed.  
 
Figure 10:  SDS-PAGE acrylamide gel 
and transfer sandwich setup.  
Left: SDS-PAGE acrylamide gel setup.  Right:  The 
transfer sandwich; electricity drives negatively 




4.11.2.5 Protein detection with antibodies 
The protocol to stain the protein of interest with antibodies was run with several permutations 
as summarised in appendix E. The PVDF membrane was blocked in 5% BSA in TBST on an 
agitating table for 2 hours at room temperature. The membrane was washed three times for five 
minutes in TBST before the primary antibody was added. Rabbit anti-p16Ink4a was made up 
in immunodiluent to a dilution of 1:1000, and incubated at 4°C overnight on an agitating table. 
The membrane underwent 4x5 minute washes in TBST before being incubated with the 
secondary antibody (anti-Rabbit HRP) diluted to 1:10 000 in TBST, for 2 hours at room 
temperature. The membrane was washed for 10 minutes, four times in TBST, and the Enhanced 
Chemiluminescence (ECL) substrate reagents were added at a 1:1 ratio (200μl of each substrate) 
for 5 minutes. The membrane was placed between two sheets of thin clear plastic, and viewed 
under the Syngene PXi Gel Imaging System (Syngene, A Division of Synoptics Ltd., MD, 
USA). 
4.12 Glial-Derived Neurotrophic Factor 
Neurotrophins such as glial-derived neurotrophic factor (GDNF) are held within intracellular 
vesicles therefore antigen retrieval or permeabilisation steps are often required to allow the 
primary antibody to bind. Several antigen retrieval methods were tested to establish a protocol 
which gave optimal staining (best signal: noise ratio).  
The primary antibody, sheep anti-GDNF, was optimised by performing serial dilutions of 1:50, 
1:100, 1:200, 1:400 and 1:800, which were then applied to serial sections from the same tissue. 
The sections were all processed together under identical conditions so that the only variable 
was the primary antibody concentration. The dilution 1:400 was selected based on optimal 
signal: noise ratio. Incubation time was also optimised to overnight at 4°C for the primary 




Sections of the same cord were cut at 16µm, and processed under standard conditions (no 
antigen retrieval), as well as with each of the following antigen retrieval methods: SDS (1% 
and 0.5%) for 30s, 1 minute and 3 minutes, heat-induced epitope retrieval with citrate buffer 
(pH 6) and heat-induced epitope retrieval with tris buffer (pH 10). From these steps it was 
concluded that the signal was not improved following any antigen retrieval protocols, therefore 
future sections were processed without antigen retrieval. 
A co-staining protocol was developed to view the co-localisation of GDNF with Choline 
Acetyltransferase (ChAT) - a specific marker of motoneurons within the spinal cord (Barber et 
al., 1984). The ChAT antibody used for this experiment was rabbit anti-ChAT. For this 
protocol, GDNF was stained as described above, followed by rabbit anti-ChAT which had 
previously been optimised at a 1:400 dilution, overnight in the fridge (4°C). The secondary, 
goat anti-rabbit Alexa Fluor® 568 was incubated for 4 hours at room temperature. Following the 
washes, the slides were treated with TrueBlack™ (Biotium, CA, USA) and mounted as described 
in section 1.8. 
4.13 Microscopy 
Stained specimens were viewed using an Olympus BX-50 upright compound microscope 
(Olympus® Corporation, Tokyo, Japan) fitted with a coolLED fluorescence illuminator (pE-1 
excitation system, coolLED Ltd, NY, USA). Images were acquired using a SPOT-RT™ Slider 
microscope camera (Diagnostic Instruments Inc., MI, USA). The microscope has three dichroic 
filters which restrict the wavelengths of excitation and emitted light; the Wide Band 
Interference (WBI) red filter (excited at 515-700nm), WBI green (580-700nm) and the UV 
narrow band filter (360-370nm) which passes blue light. The images were photographed in 
RGB (red, green and blue) using the 40x objective oil immersion lens. The exposure time, LED 
illumination and gain were set using the sample with the brightest staining for each antibody 
and the exposure and illumination parameters were then kept constant across all images taken 
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for each antibody. This ensured the images were comparable, and that relative fluorescence 
intensity could be used as an indicator of protein amount within the tissue. 
4.14 Analysis and statistics 
Protein immunostaining was quantified by acquiring mean greyscale values of images of 
stained areas. All images were taken in RGB to allow non-specific fluorescence to be 
eliminated, therefore images were initially loaded onto ImageJ and split into the three respective 
channels. The data from the two channels not of interest was discarded, and the data from the 
channel of interest was analysed.  
4.14.1  GFAP 
The green channel data was loaded into Ilastik, an Interactive Learning and Segmentation 
software (Heidelberg Collaboratory for Image Processing (HCI), Germany). Ilastik was trained 
using pixel classification to identify GFAP immunofluorescence and exclude background. Once 
Ilastik was trained on six images and could reliably separate staining from background, the 
parameters obtained by the program were applied to all images using batch processing. The use 
of Ilastik to batch process all images eliminates subjectivity, as the same selection criteria are 
applied to all images. A mask was generated for each image and used to identify the area for 
Figure 11: Mask of GFAP immunostaining generated by Ilastik. 
A) Binary image produced by Ilastik showing a mask of white astrocytic staining on a black 




analysis (Fig. 11). The mask and green channel data were loaded into Fiji software (Schindelin 
et al., 2012), and mean fluorescence intensity within the mask was measured as an average 
grayscale value.    
GFAP average greyscale values were statistically analysed using a linear mixed-model (LMM) 
on RStudio (R Core Team, 2013) which analyses both the fixed effects such as age and exercise, 
and random effects such as intra-individual variation. P values were acquired by calculating 
standard error from the two groups to be compared, and then calculating the Z statistic by 
dividing the difference in the two averages by the standard error (Altman & Bland, 2011). The 
Z statistic was then inserted into the following equation: 
0.717𝑥𝑍 –  0.416𝑍2 
4.14.1  P16 
Ten images were acquired from the lumbar lateral motor column per animal (n=5). Images of 
DAPI immunostaining of nuclei (blue channel), p16 immunostaining (red channel) and GFAP 
immunostaining (green channel) were merged using Adobe® Photoshop® (Adobe Systems 
Inc., CA, USA) to allow the identification of co-localisation of p16 immunostaining within 
astrocyte nuclei. Co-staining with GFAP was analysed qualitatively, as the total number of 
individual astrocytes could not be determined due to the nature of the GFAP immunostaining 
in relation to the size and shape of astrocytes.  
P16 co-localisation with ChAT immunostaining was not analysed due to the incompatibility of 
the ChAT and p16Ink4a antibodies causing the staining to be indistinguishable between the two 
proteins. In view of this limitation, ImageJ was used to measure the diameter of cells with 
cytoplasmic anti-p16 staining present. Both the longest axis of the cell, and perpendicular to 
that axis (orthogonal axis) were measured and the two values averaged to obtain a final 
diameter. Unpublished data from the Sheard lab found that because a cell body is not a sphere, 
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taking the longest axis may confound the results by over-estimating cell size, and the shortest 
axis may underestimate the cell size. 
4.14.2 GDNF 
Images of GDNF/ChAT co-stained tissues were analysed by acquiring the mean grayscale value 
of GDNF immunostaining within the boundaries of the anti-ChAT stained motoneurons. First, 
the RGB images were split into the respective channels, and the red channel data (ChAT 
staining) was loaded into ImageJ software to generate a mask for motoneurons. An appropriate 
threshold was chosen which most accurately distinguished motoneurons from background, and 
a minimum size threshold was established to exclude small areas of background that the mask 
had selected. This mask was then loaded into Fiji software (Schindelin et al., 2012) with the 
green channel data (GDNF staining), and the mean grayscale value of the GDNF 
immunofluorescence within the boundaries of the mask was measured. 
Due to the appearance of bright staining within the nucleus of the young and elderly exercised 
animals which is abnormal for both ChAT and GDNF, analysis was repeated to measure only 
cytoplasmic GDNF levels, eliminating the potentially artefactual bright nuclei which may 
confound the results. To do this, GDNF images were loaded into ImageJ and the channels were 
split, disregarding the blue and red channel data. The motoneurons were circled by hand, 
followed by the nuclei. The area between these two circles was then analysed for mean 




Statistical analysis was performed as described for GFAP (Section 1.14.1) using mean 
greyscale values from each cell cytoplasm and performing a linear mixed model (LMM) using 
RStudio (R Core Team, 2013). 
  
Figure 12: Analysis of cytoplasmic GDNF levels 
Once the channels were split, the green channel image was analysed by circling the cell soma, followed 
by the nucleus, and measuring the greyscale value of only the cytoplasm (area between the two 
circles). B) Data in line 1represents the mean greyscale value within the whole cell, line 2 represents 

















5.1 Elimination of technical and processing artefacts 
5.1.1 Freezing artefact 
Optimisation of tissue freezing was crucial for allowing quality immunohistochemistry to be 
performed on tissue sections. The following results are images of GFAP-labelled, 16um 
sections of mouse spinal cord, within the lateral lumbar column. If the spinal cords are not 
frozen adequately, ice crystals may pierce holes through the tissue, or the innermost parts of the 
tissue may begin to degrade in the freezer, resulting in little-to-no immunostaining of these 
regions. Below are images of GFAP-labelled sections, which contain freezing artefact.  
Spinal cords were frozen using specific techniques to avoid formation of ice crystals during 
freezing (Section 2.6). Quality freezing techniques provide the basis for optimal 
immunostaining of proteins within the tissue.  
 
  
Figure 13: Freezing artefact 
Images of anti-GFAP-immunostained sections of elderly spinal cord show the grey matter has 




5.1.2 Lipofuscin granules and tissue autofluorescence 
Due to the increasing presence of lipofuscin in aged tissues, all images were taken in RGB to 
allow the channels to be split, and only the data from the desired channel to be analysed, 
disregarding non-specific fluorescence. This is particularly important as lipofuscin granules are 
autofluorescent and appear yellow or orange under the microscope. Figure 14 shows the same 
image taken in RGB and then fluorescence green, demonstrating how lipofuscin is no longer 
distinguishable from AlexaFluor™488 staining when imaged in green. TrueBlack™ (Biotium, 
CA, USA) was used to reduce the visibility of lipofuscin and tissue autofluorescence for all 
tissue sections from all age groups following the immunohistochemistry protocol, prior to 
mounting (Fig. 15).  
  
Figure 14: Images of GFAP immunostaining containing lipofuscin granules  
A) Image of GFAP-immunostained elderly spinal cord taken in RGB with lipofuscin granules (indicated 
by arrows) appears a dark orange colour. B) The same area imaged in fluorescence green; the same 
lipofuscin granule (indicated by arrow) appears green. (Scale bars = 50μm). 
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5.2 Glial Fibrillary Acidic Protein  
5.2.1 Immunohistochemistry 
As described in the methods section, each antibody was optimized via various permutations of 
the protocol to ensure optimal signal to noise ratio was achieved. Due to the extensive nature 
of astrocytic projections - a single astrocyte can span up to 40μm (Cirillo et al., 2012) - section 
thickness was optimized for GFAP immunostaining to achieve low background fluorescence, 
but allow visualization of single astrocyte profiles. Figure 15 shows GFAP immunostaining of 
sections cut at 6μm (A), 16μm (B), and 16μm imaged at 6 planes of focus and assembled as a 
focus composite (C). By compiling the images as a stack, it allows for visualization of extensive 
astrocytic projections through multiple focal planes. By overlaying the stacked image with 
DAPI staining of nuclei, it allowed distinction of astrocyte cell bodies and their associated 
projections. Images B-D were acquired from elderly tissues which were treated with 
TrueBlack™.
 
Figure 15: Anti-GFAP immunostaining of sections of multiple thicknesses                                                               
A) 6μm thick section showing astrocytic staining with little distinction of whole astrocytic profiles. B) 16μm 
thick section showing astrocytic profiles. C) Pseudo-confocal stack of 6 planes of focus showing astrocytes 
and their projections (example indicated by arrow). D) Focus composite stack of 6 planes of focus showing 





Figure 16 demonstrates anti-GFAP staining in sections of spinal cord from young, elderly 
sedentary and elderly exercised animals. There appears to be a higher quantity of anti-GFAP 
staining within each astrocyte visible in an image and more astrocytic projections are visible in 









Figure 16: GFAP immunostaining in 
young, elderly sedentary and elderly 
exercised mouse lumbar lateral motor 
column. 
 GFAP immunostaining in A) young, B) elderly 
sedentary, and C) elderly exercise mouse lumbar 
lateral motor column. D is a negative control in 
which the primary antibody was omitted. (Scale 
bar = 50μm). 
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5.2.2 Statistical analysis of GFAP immunostaining 
Statistical analysis was performed using a linear mixed model (LMM) on R software (R Core 
Team, 2013). There was a strong trend toward an increase in GFAP levels between young and 
elderly sedentary groups, but this was not statistically significant (p=0.052). In addition to this, 
there was no difference in GFAP levels between elderly sedentary and elderly exercised animals 
(p=0.12) (Fig. 18).  
 
  
Figure 17: Changes in GFAP staining levels with age and exercise.  
The above graph shows average greyscale value of GFAP immunostaining in young, elderly sedentary and 
elderly exercised spinal cord. A linear mixed model was used to calculate statistical values. There was a trend 
toward an increase between young and elderly sedentary which was not statistically significant (p=0.052), and 




5.2.3 GFAP staining intensity and average distance run by exercised animals  
The two data sets of GFAP immunostaining and average distance travelled per day for each 
animal were plotted together to establish if there was an observed correlation between the two 
data sets. The results show no observable trend between distance travelled and GFAP levels 




Figure 18: Changes in GFAP staining plotted with average distance run per day.  
The above graph shows average greyscale value of GFAP immunostaining elderly exercised animals, plotted 
with the average distance in kilometres run by each animal. The results demonstrate no relationship between 





P16 is a cyclin-dependent kinase inhibitor and marker of cell-cycle arrest (Baker et al., 2008). 
P16 was chosen for this study as is the most widely used senescence marker in the literature, 
but there is low availability of well-established antibodies against p16 for use with fluorescence 
immunohistochemistry. Due to initial difficulties in visualizing p16 immunostaining in mouse 
lumbar lateral motor column, the rabbit anti-p16Ink4a antibody was run on sections of positive 
control tissue provided by the Department of Pathology, University of Otago, to establish the 
reliability for future use as a senescence marker in sections of spinal cord. 
5.3.1 Positive control 
Mouse lung carcinoma tissue was used as the positive control for p16 immunostaining as 
tumours are known to have high expression of p16 (Shapiro et al., 1995; Shapiro et al., 
1995)(Witkiewicz et al., 2011). Figure 19 shows tumour cells which are positive for p16 with 
diffuse cytoplasmic staining which is described in the literature as a characteristic of various 
cancers including lung carcinoma (Shapiro et al., 1995; Evangelou et al., 2004). Images were 
mounted with DAPI mounting medium (appendix A) to allow overlay of the nuclear stain.  
 
Figure 19: Positive control staining for p16 
P16 positive staining of mouse lung carcinoma tissue. A and C show clusters 
of cells with diffuse cytoplasmic anti-p16 staining. B and C show DAPI staining 




5.3.2 P16 and GFAP  
To inform the aim of investigating whether astrocytes become senescent in the lumbar lateral 
motor column with age, a co-staining protocol was established for p16 and GFAP.  
A staining protocol was established to allow the visualisation of co-localisation of p16 with 
anti-GFAP staining of astrocytes, and DAPI to identify cell nuclei. Figure 20 is a representative 
image showing the three staining components (A, B and C), and then the final combined image 
(D). Images were qualitatively analysed based on observations of p16 co-localisation with 
GFAP immunostaining. It was observed that p16 does not co-localise with astrocyte nuclei 
(indicated by arrows), as no astrocyte nuclei were positive for p16 immunostaining. Anti-P16 
staining appears within nuclei of another cell type within the lumbar lateral motor column. 
 
 
Figure 20: P16 co-staining with GFAP and DAPI.  
The above figure shows triple-immunolabelling of A) p16, B) GFAP and C) DAPI staining of nuclei. Image C 




Figure 21 shows the appearance of p16-positive nuclei within the lumbar lateral motor column 
of elderly mice.  Exercise did not have a visible effect on reducing the number of p16-positive 
nuclei although this was not quantified. 
 
 
5.3.3 P16 positive motoneurons 
Due to the incompatibility of the rabbit anti-p16Ink4a antibody and the rabbit anti-ChAT 
antibody, co-staining of these two proteins was performed but the resulting immunostaining 
was indistinguishable for the two proteins and therefore was not analysed. Images acquired of 
p16 co-stained with GFAP show p16-positive nuclei in the lumbar lateral motor column of 
elderly mice, and diffuse cytoplasmic staining of cell bodies (Fig. 22). 
Figure 21: P16 immunostaining of 
the lumbar lateral motor column of 
young, elderly sedentary and elderly 
exercised mice.  
The figure above shows images of the lumbar 
lateral motor column triple-stained with p16 
(red), GFAP (green) and DAPI (blue). A) Young, 
B) Elderly sedentary and C) Elderly exercised. 
D) Negative control with p16 primary antibody 





Due to the limitation of being unable to co-stain with ChAT to confirm the p16 positive cells 
are motoneurons, ImageJ was used to measure the diameter of both the longest axis of the cell, 
and then perpendicular to that axis (orthogonal axis) (Fig. 23). The two values were then 
averaged to determine a final diameter. Analysis of soma diameter of the cells containing p16 
positive staining revealed the diameters of the 4 cells measured to be: 37.3μm, 39.1μm, 35.5μm 
and 36.2μm, consistent with what is documented in the literature for motoneuron diameter 
(Ishihara et al., 2001). 
 
Figure 23B shows the mean greyscale values of 4 cells, each pair of values represents first the 
longest axis of the cell body, and then perpendicular to that axis. Each pair of means was 
averaged to calculate diameter of the cells. 
Figure 22: P16 positive staining in motoneurons  
A) P16 positive staining overlaid with anti-GFAP staining. Diffuse cytoplasmic staining is visible 
around the positive nucleus. B) P16, GFAP and DAPI triple-labelling shows p16 appears positive 
within the nucleus. Negative control bottom right. (Scale bar = 50μm) 
Figure 23: Analysis of p16-positive motoneurons 
To confirm the p16-positive cells as motoneurons, the diameter of the longest axis of the cell, and perpendicular 
to that axis (orthogonal axis) were measured to give an average of the two which was used as the actual diameter 




5.3.4 Western blot 
The western blotting technique was optimized to visualize p16 and allow for quantification of 
fold-change of p16 expression within young versus elderly sedentary spinal cord tissue. The 
initial blot was run with varying amounts of protein loaded into the wells: 10, 20, 40 and 80μg. 
The blot shows bands at 16kDa for the 10 and 20μg with high background, and no 
distinguishable band for the higher amounts as there was too much protein to be separated out 
effectively. The white marks indicated by the arrows are the bands of the protein ladder 
indicating the levels of molecular weights.  
 
The first western blot performed allowed optimization of protein loading amount for future 
blots. The optimisation blot shows bands present at 16kDa with high background staining, but 
no bands clearly visible with 40 and 80μg of loaded protein (Fig. 25A). Due to time restraints 
and antibody availability, the western blot technique was not optimised to a level which allowed 
for quantification of fold change in p16 levels between young and elderly spinal cord. A 
resulting blot shows bands at 16kDa which appear larger in elderly samples, but this is only 
speculative as staining of the loading control was unsuccessful which is required for reference. 
  
Young (n=5) Elderly (n=5) M M 
B 
μg 
Figure 24: Western blot results  
A) Western blot showing bands at 16kDa within the lanes loaded with 10 and 20μg of protein but protein 
overloading with 40 and 80μg of protein. B) Resultant blot which shows the marker (far left band) at 15kDa 
and bands of anti p16-staining present at 16kDa, which appear to be thicker in the elderly group. (M = 




5.4 Glial-Derived Neurotrophic Factor 
5.4.1 Immunohistochemistry 
Sections of mouse spinal cord were co-stained with sheep anti-GDNF and rabbit anti-ChAT to 
measure levels of in GDNF within spinal motoneurons. Figure 25 shows immunostaining of 
ChAT and GDNF, and the result of the two combined images with DAPI to label nuclei. GDNF 






Figure 25: Glial-Derived Neurotrophic Factor (GDNF) triple-labelling 
Figure above shows staining of A) Choline-Acetyl Transferase (ChAT) within motoneurons, B) 
GDNF and C) ChAT overlaid with Glial-Derived Neurotrophic Factor (GDNF) and DAPI. Images D 




Images acquired from the lumbar lateral motor column show motoneurons with GDNF staining 
within the nucleus and the cytoplasm (Fig. 26). The GDNF staining pattern shows vesicle-like 
staining around the motoneurons, consistent with what is documented in the literature 
(McCullough et al., 2013). GDNF staining is visibly brighter in the elderly exercised group 
compared to both the young, and the elderly sedentary groups. Important to note is that the 
images acquired for the elderly exercised group were taken at half the gain of the other two 
groups due to the level of brightness resulting in saturation. This meant that the resulting 







Figure 26: GDNF immunostaining in 
young, elderly sedentary and elderly 
exercised mouse lumbar lateral motor 
column. 
 The above figure shows images of Glial-
Derived Neurotrophic Factor (GDNF) 
immunostaining in A) young, B) elderly 
sedentary, and C) elderly exercise mouse 
lumbar lateral motor column. D is a negative 
control in which the primary antibody was 




5.4.2 Statistical analysis of GDNF immunostaining of motoneurons 
Analysis of the changes in GDNF immunostaining was performed using a linear mixed model 
(LMM) on R software (R Core Team, 2013). The results showed that there was no change in 
the level of GDNF between young and elderly sedentary animals, but a significant increase was 








Figure 27: Changes in GDNF staining levels with age and exercise.  
The above graph shows average greyscale value of Glial-Derived Neurotrophic Factor (GDNF) 
immunostaining of motoneurons in young, elderly sedentary and elderly exercised spinal cord. A linear 
mixed model was used to calculate statistical values. There was no change in average greyscale value 
between young and elderly sedentary, but a significant increase in GDNF level between elderly sedentary 




5.4.3 Statistical analysis of GDNF immunostaining within motoneuron 
cytoplasm  
Analysis of the changes in GDNF immunostaining within motoneuron cytoplasm in young, 
elderly sedentary and elderly exercised spinal cord was performed using a linear mixed model 
(LMM) on R software (R Core Team, 2013). By excluding the nuclear compartment in the 
analysis, the average greyscale value of the elderly exercised group was reduced from 136 to 
123, whereas the other two groups were unaffected. The observed trends are unchanged, with 






Figure 28: Changes in cytoplasmic GDNF staining levels with age and exercise.  
The above graph shows average greyscale value of Glial-Derived Neurotrophic Factor (GDNF) 
immunostaining of motoneuron cytoplasm within young, elderly sedentary and elderly exercised spinal 
cord. A linear mixed model was used to calculate statistical values. There was no change in average greyscale 
value between young and elderly sedentary, but a significant increase in GDNF level between elderly 





5.4.4 GDNF staining levels and average distance run by exercised animals  
The two data sets of GDNF immunostaining and average distance travelled per day for each 
animal were plotted together to establish if there was an observed correlation between the two 











Figure 29: Changes in GDNF staining plotted with average distance run per day 
 The above graph shows average greyscale value of Glial-Derived Neurotrophic Factor (GDNF) 
immunostaining elderly exercised animals, plotted with the average distance in kilometres run by each 




5.5 Exercise levels of elderly exercised animals 
 
Animal 1 2 3 4 5 
Total distance 
travelled 
805 478 216 393 709 
Average distance 
per day 
6.7 3.9 1.8 3.2 5.8 
 
For the exercise protocol, elderly animals were individually housed with free access to a 
running wheel which was fitted with a device to track the distance travelled by each animal. 
Table 3 shows the large amount of variance in amount of exercise performed by each animal, 
varying from <2km - almost 7km per day on average, consistent with what is reported for 
both the C57Bl/6 breed, and for the 20-month age group (van Praag et al., 1999; Goh & 
Ladiges, 2015).  
















This study investigated astrocytes as drivers of motoneuron death and subsequent loss of muscle 
mass with ageing. The primary aims of the current study were to determine whether astrocytes 
in the aged mouse lumbar lateral motor column are becoming senescent, and whether the 
emergence of this phenotype can be prevented or reduced by late-life endurance exercise. This 
study aimed to investigate changes in GDNF - the most potent neurotrophic factor associated 
with motoneuron survival (McCullough et al., 2013), with age and exercise, and the potential 
of this trophic factor to attenuate the senescent or reactive phenotype of astrocytes.  
6.1 The rodent model for investigating sarcopenia 
It is worth noting that the current study uses a rodent model to investigate the effects of ageing 
on various parameters of the neuromuscular system. The C57B/6 mouse line was chosen due 
to the observed similarities in age-related musculoskeletal decline - reflecting both the 
characteristics and relative age of onset of decline observed in humans (Ballak et al., 2014). 
Mice age much more rapidly than humans, therefore the effects of ageing are interpreted based 
on relative lifespan - also expressed as percentage of mean life span (MLS) (24 month-old mice 
show a similar degree of age-associated decline to a 70 year-old human) (Ballak et al., 
2014)(The Jackson Laboratory, 2017).  
Despite the fact that rodents are not directly comparable to humans, the mouse model serves as 
a useful tool in understanding the relative effects of ageing on the muscular system, and 
provides useful insight into what may be occurring the ageing human neuromuscular system. 
6.2 Astrogliosis and astrocyte reactivity 
Reactive gliosis describes the process by which astrocytes react to insults of the CNS, either 
mild such as with ageing, or severe insults such as physical injury (Sofroniew & Vinters, 2010). 
Consistent with the literature, the current study demonstrated that GFAP levels were low in 
63 
 
young lumbar lateral motor column, with only a few astrocytic processes visible in images taken 
from this region. This indicates that astrocytes within the young lumbar lateral motor column 
are functioning normally and show no signs of astrogliosis or reactivity (Fig. 30). GFAP is not 
essential for the function of healthy astrocytes, therefore is often at low levels or undetectable 
in nervous tissue from healthy rodents, but is necessary for astrogliosis or glial scar formation 
(Faulkner et al., 2004; Sofroniew, 2009). 
Consistent with the hypothesis, there was a visible increase in anti-GFAP staining levels within 
elderly sedentary mouse lateral motor column compared to that of young, indicating that 
astrocytes are undergoing a transition toward a reactive state. The response of increased GFAP 
levels within astrocytes with ageing relates to the age-associated accumulation of oxidative 
damage such as lipoperoxidation, and other cellular stresses that drive astrocytes to become 
reactive (Sofroniew & Vinters, 2010). Astrocytes are sensitive to low levels of H2O2, and are 
therefore more susceptible to the oxidative stresses accumulated with age (Mombach et al., 
2015). Although this change in GFAP levels failed to reach statistical significance with my 
method of quantification (p=0.052), the observed trend demonstrates that astrocytes are 




Based on the nature of mild astrogliosis which has been associated with ageing,  it is likely that 
the increased GFAP levels are due to more GFAP per astrocyte, which can often be mistaken 
for proliferation of astrocytes that occurs as a result of severe CNS insult such as with injury or 
disease (Sofroniew, 2009). Although to the naked eye, it would appear that there are more 
astrocytes in an image taken from an elderly lateral motor column compared to a young, this is 
because GFAP is not present at detectable levels in all astrocytes of a healthy CNS as described 
above (Sofroniew & Vinters, 2010) (Fig. 30). Therefore, when GFAP is upregulated within 
astrocytes with their transition to the reactive state, this results in more detectable astrocytes 
with anti-GFAP immunostaining, but not necessarily more astrocytes. Proliferation of 
astrocytes is associated with severe trauma or disease of the CNS, which is not comparable to 
the level of cellular stresses observed with normal ageing (Faulkner et al., 2004). 
Due to the extensive nature of astrocytic projections which span up to 40 microns in diameter, 
the techniques used to evaluate astrocyte reactivity resulted in a limited perspective of astrocyte 
morphology. Sections were cut at 16 microns to optimise immunostaining of GFAP. To 
Figure 30: Degrees of astrogliosis 
Schematic representation of the gradation of degrees of astrogliosis and 
their corresponding levels of GFAP expression and cellular proliferation. 
(Figure adapted from (Sofroniew & Vinters, 2010)) 
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visualise astrocytes in their entirety and evaluate morphological changes such as hypertrophy 
of projections, confocal microscopy would be required which would be a useful addition to the 
current findings. This method would add depth to our understanding of changes in amount of 
GFAP within an astrocyte with ageing and subsequent morphological changes associated with 
the reactive phenotype. 
A minor limitation of the methods used in this study, was the inability to distinguish whole 
individual astrocytes within an image. This limitation resulted in the number of data points for 
analysis being limited to the number of images, instead of number of cells, giving fewer data 
points per animal and weaker statistical power. Image analysis was performed using Ilastik, an 
Interactive Learning and Segmentation software (Heidelberg Collaboratory for Image 
Processing (HCI), Germany). Ilastik was trained to recognise astrocytic staining and exclude 
background. By using a computer learning programme to select astrocytic staining, all selection 
bias was avoided as all regions containing anti-GFAP staining were included in the analysis, 
regardless of brightness. In addition to this, batch processing ensures that identical selection 
criteria were applied to every image, so trends in change of GFAP immunostaining are real, but 
did not reach statistical significance as a consequence of the methods used. 
The observed level of astrocytic reactivity is not categorised as severe, but may still hold 
significance in terms of astrocytic neuroprotective capacity of motoneurons with ageing. 
Astrogliosis is a graded response, not an all-or-none response, therefore any level of reactivity 
will negatively impact astrocytic function to an extent (García-Matas et al., 2008; Sofroniew, 
2009). Functional alterations of reactive astrocytes include the induction of NF-kB signalling 
pathways which induce a neuroinflammatory response (Brambilla et al., 2009). This 
inflammatory phenotype of astrocytes has been implicated in the accelerated death of 
motoneurons observed in ALS, as well as with normal ageing (Brambilla et al., 2009; Das & 
Svendsen, 2015; Rodríguez-Arellano et al., 2016). The age-associated reduction in astrocytic 
function is deleterious to the neurons it supports, which provides a mechanism by which 
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astrocytes contribute to the death of motoneurons observed with ageing. The observed increase 
in GFAP, indicative of astrocyte reactivity, supports the initial hypothesis suggesting age-
associated astrocyte reactivity as a driver for motoneuron death, and the resulting loss of muscle 
mass associated as a consequence of denervation. 
Exercise was hypothesised to reduce changes in astrocyte reactivity with age, based on the 
understanding that exercise reduces age-associated oxidative stress and inflammation (Schafer 
et al., 2016). Interestingly, conflicting results suggest that exercise may have the opposite effect, 
as rats which were subjected to daily treadmill running demonstrated an increased GFAP 
expression within the hippocampus (Saur et al., 2014). These findings were suggested to reflect 
an increase in astrocyte metabolism and protein synthesis, implying a healthy response to 
increased physiological demand (Saur et al., 2014). Despite these findings, the abundance of 
literature reports an exercise-induced reduction in GFAP levels in the context of reducing 
astrogliosis and the associated chronic inflammation observed (Bernardi et al., 2013; Kim et 
al., 2014). 
Results from this study reported no significant change in GFAP levels following 4 months of 
exercise in late life, which refutes the initial hypothesis. The lack of correlation observed 
between GFAP levels and amount of exercise also indicates that the level of exercise had no 
observed effect on GFAP expression. To address the discordance of this finding with current 
literature, the studies referenced above subjected their animals to walk or run a given distance 
on a treadmill each day, which may differ in the level of exertion as well as the distance run 
by mice which run as they choose. In addition to this, there is little data reporting on exercise-
associated changes in GFAP within the spinal cord, as the studies referenced above measured 
GFAP levels of various brain regions which are not necessarily affected by exercise to the 
same extent. The current findings indicate that the protective mechanism by which exercise 
reduces the effects of sarcopenia, and protect against motoneuron death with age are not due 
to a reduction in astrogliosis and astrocyte reactivity.  
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Astrocytes have been widely implicated as contributors to age-associated neurodegeneration 
and neurodegenerative conditions in their reactive state (Bhat et al., 2012; Rodríguez-
Arellano et al., 2016). Here, we report that astrocytes show an age-related transition toward 
a more reactive state, and therefore may show reduced support to motoneurons, contributing 
to their death with ageing. In view of these findings, the next aim of this study was to identify 
the driver of this astrocytic transition to the reactive state, in particular, cellular senescence 
which has been suggested as a driver of astrogliosis and neuro-inflammation with ageing 
(Bitto et al., 2010; Childs et al., 2015).  
6.3 A new role for senescence in the ageing neuromuscular system? 
A characteristic of ageing is the accumulation of senescent cells in tissues (Hewitt et al., 2012; 
van Deursen, 2014; Hall et al., 2016).  Senescent astrocytes contribute to the observed age-
associated inflammation of the CNS via their senescence-associated secretory phenotype 
(SASP), and have been implicated in the pathology of various neurodegenerative diseases 
(García-Matas et al., 2008; Das & Svendsen, 2015; Rodríguez-Arellano et al., 2016). This study 
aimed to find out if the accumulation of senescent astrocytes in the ageing lumbar lateral motor 
column could be contributing to the loss of motoneurons with age. 
Immunohistochemical detection of p16Ink4a, a cyclin-dependent kinase inhibitor and the most 
commonly used marker of cellular senescence (Serrano et al., 1993; Matjusaitis et al., 2016), 
revealed the presence of p16-positive nuclei within the lumbar lateral motor column of aged, 
but not young mice. Surprisingly, these p16-positive nuclei did not coincide with GFAP 
immunostaining of astrocytes as has been observed in the brain (Bhat et al., 2012). A western 
blot was performed to attempt to quantify this increase, but due to time restraints this was not 
optimised to allow for analysis of the blots. Although this was not analysed, it appeared there 
were larger bands at the level of 16kDa for elderly versus young spinal cord tissue, supporting 
the immunohistochemistry results that p16 expression is up-regulated in elderly spinal cord 
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with age. The observed lack of co-localisation of p16-positive nuclei with astrocytic GFAP 
staining refutes the hypothesis that astrocytes are becoming senescent with age and contributing 
to the death of motoneurons. This means that the reactive phenotype of astrocytes observed 
with age may still be implicated in motoneuron death via a reduced neuroprotective capacity, 
but this is not a consequence of cellular senescence. 
The abundance of literature which describes the implications of astrocyte senescence on 
function of the CNS is based on neurodegenerative diseases of the brain and spinal cord such 
as Alzheimer’s disease and ALS (Bhat et al., 2012; Das & Svendsen, 2015). These conditions 
differ in their location within the CNS as well as their severity compared to normal ageing. In 
addition to this, the study which demonstrated the detrimental effect of senescent astrocytes on 
motoneurons survival, did so in culture conditions which are not necessarily translatable to in 
vivo conditions or in whole tissues (Das & Svendsen, 2015; Sharpless & Sherr, 2015). Astrocyte 
senescence may be a characteristic of ageing astrocytes within the brain or associated with 
neurodegenerative disease, but based on current findings; not a characteristic of the ageing 
neuromuscular system and therefore not a contributor to motor neuron death, refuting the 
hypothesis. 
An important idea to discuss is the abundance of research on senescence performed in vitro, 
and its translation into living tissues and systems. A recent Nature review by (Sharpless & 
Sherr, 2015) discusses the caveats of applying the findings of in vitro investigation to living 
organisms. In contrast to the conditions in a culture dish, there is a large amount of 
heterogeneity in cells of whole tissues which makes identifying and characterising senescence 
in vivo a complex task. Studies which investigate senescence in vitro often induce this response 
by administering hydrogen peroxide to mimic the oxidative stress observed in whole tissues 
with ageing (Bitto et al., 2010). The consequences of direct treatment with peroxide are not 
necessarily a direct reflection of the mechanisms in which age-associated cumulative oxidative 
damages affect astrocytes in living tissue. It is for this reason that the role of senescence in vivo 
69 
 
may be over-estimated by the methods which are used to conclude its importance, as indicated 
by the current findings which dismiss senescence as a driver of the reactive transition of 
astrocytes of the lumbar spinal cord with ageing. 
 Although astrocytes did not show upregulation of p16 indicative of senescence, anti-p16Ink4a 
staining was present in larger nuclei of the ageing lateral motor column, some of which 
contained diffuse, cytoplasmic staining the size of lumbar motoneurons (Ishihara et al., 2001). 
There is no literature describing the appearance of senescent motoneurons with age, which 
makes the observed anti-p16-Ink4a staining within motoneuron nuclei an unexpected result. 
The co-localisation of p16 and motoneuron cell nuclei was unable to be confirmed with Choline 
Acetyltransferase (ChAT) co-staining, therefore the interpretation of this result remains 
speculative.  
The presence of p16 within nuclei of the lumbar lateral motor column could lead to the 
assumption that these cells express a SASP which results in a chronic inflammatory 
microenvironment, as observed in culture of senescent cells (Bitto et al., 2010). It is important 
to remember that senescence is a mechanism to halt the proliferation of damaged cells, therefore 
when p16 expression is observed in already terminally differentiated cells, the implications of 
its expression require further investigation. It has been demonstrated that induction of 
senescence in human fibroblasts via ectopic expression of p16Ink4a resulted in cell-cycle arrest 
without a resultant SASP (Coppé et al., 2011). The observation that cell-cycle arrest can occur 
without a consequent SASP signifies that the SASP is not a result of p16 expression or the 
senescent phenotype, but a response to damage, independent of growth arrest (Coppé et al., 
2011). Therefore, the presence of p16 within the lumbar lateral motor column may not be a 




The resultant changes associated with p16 expression within motoneurons with ageing may not 
be as a consequence of a SASP, but another downstream pathway. The expression of 
phosphorylated Rb and E2F (two known downstream targets of p16 in the induction of 
senescence) (Fig. 4) was observed within ALS-affected motoneurons which stained positive for 
TUNEL and caspase-3, two known markers of apoptosis (Ranganathan & Bowser, 2010). In 
view of this finding, the observed increase in p16 expression may be indicative of induction of 
motoneuron cell death, a proposed driver for atrophy of muscle fibers and sarcopenia. 
Further experimentation is needed to investigate this finding in terms of the presence of p16 
within motoneurons within the lateral motor column, and the consequences of this expression. 
It would be useful to measure circulating cytokines and interleukins to determine if there is a 
SASP associated with the p16 expression observed. Based on the finding that p16 expression 
co-localises with markers of apoptosis in spinal cord of ALS-affected humans, it would be 
useful to co-stain the mouse lumbar lateral motor column with p16 and TUNEL or caspase 3, 
to confirm that motoneurons may be fated to apoptosis. In view of the aims and hypotheses of 
the current study, in can be concluded that senescence is not a driver for motoneuron death due 
to the deleterious effects of the SASP. Instead, p16 expression may directly precede 
motoneuron cell death, which drives the loss of muscle mass via the afore mentioned, disuse 
atrophy. 
6.4 Glial-Derived Neurotrophic Factor increases with exercise: 
Implications for motoneuron survival 
The next aim of this study was to investigate changes in a critical trophic factor for 
motoneurons: glial-derived neurotrophic factor (GDNF). GDNF is required for the survival and 
proliferation of motoneurons (Gyorkos et al., 2014). I hypothesised that GDNF would reduce 
with age, potentially as a result of the reduction in skeletal muscle mass observed with age and 
consequent loss of retrograde supply to motoneurons. The findings in the current study 
demonstrated that there was no significant reduction of GDNF in the lumbar lateral motor 
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column with age, refuting my hypothesis. This finding indicates that an age-associated 
reduction in GDNF levels within lumbar lateral column motoneurons is not a contributor to 
motoneuron death with ageing. 
Despite the lack of difference in amount of GDNF within the lumbar lateral column of mice 
with ageing, current findings reported a marked increase in the level of GDNF of elderly 
exercised compared to elderly sedentary animals, consistent with previous findings (Côté et al., 
2011; McCullough et al., 2013). This is an interesting result, as exercise appears to increase 
levels of GDNF irrespective of an age-associated reduction, implying that exercise may have 
the same effect on young motoneurons. The increased GDNF levels showed no correlation with 
amount of exercise which indicates that the ability of skeletal muscle to increase its production 
of GDNF is not limitless, but has a maximal rate which cannot be exceeded with further 
exertion.  
In the context of sarcopenia, this result demonstrates that the protective effects of exercise 
against neuromuscular deterioration are observed with even moderate levels of activity. The 
activity level of the mice in this study was consistent with what has previously been reported 
for the C57Bl/6 breed, and for the 20-month old age group (van Praag et al., 1999; Goh & 
Ladiges, 2015). The recorded running levels indicate that one animal ran almost four times that 
of another animal from the same cohort, yet the observed increase in the trophic factor, GDNF 
were unaffected by level of exertion. This finding gives a strong indication that low-level 
exercise is sufficient to increase the skeletal-muscle trophic supply of GDNF to motoneurons, 
and exert benefits in enhancing motoneuron survival and slowing progression of sarcopenia in 
late-life. 
It would be useful to further characterise the effect of exercise by including a cohort of young 
exercised animals to determine if the same increase in GDNF level is observed. It would also 
be beneficial to run animals at varying given levels of exercise, limiting the amount of exercise 
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for some animals to determine the amount of exercise required to increase GDNF levels, and 
ascertain the level at which the increase in GDNF plateaus.  
Although the effects of an exercise-induced increase in spinal motoneuron GDNF levels were 
not assessed, in can be incurred from the literature that upregulated GDNF levels have various 
benefits for motoneuron survival (Henderson et al., 1994). In particular, overexpression of 
GDNF in skeletal muscle has shown potent effects on neuromuscular remodelling, NMJ 
innervation, motoneuron survival and motor performance in aged and SOD1 mutant mice (Li 
et al., 2007; McCullough et al., 2013; Park & Höke, 2014). It would be interesting to further 
characterise these effects in this mouse model, and investigate whether a correlation is observed 
between GDNF levels and motoneuron survival, as well as effects on NMJ innervation. These 
investigations would provide insight as to how GDNF may play a role in attenuating the 
progression of sarcopenia, by reducing motoneuron loss and subsequent muscle fiber disuse 
atrophy. 
Overall, the reported exercise-induced GDNF increase supports the hypothesis that exercise 
may induce an activity-dependent increase in skeletal muscle-derived GDNF, which is 
transported back to motoneuron cell bodies in the lumbar lateral motor column to exert its 
protective effects. This finding demonstrates the potential protective role of exercise against 
motoneuron loss with age, irrespective of the age at which exercise was initiated, and 
irrespective of amount of exercise performed. 
As mentioned in the results section, the observed staining pattern of GDNF included bright 
staining within the nucleus for both GDNF and ChAT, an unexpected result. Previous 
investigation of the effects of exercise on GDNF levels within motoneurons revealed a staining 
pattern similar to what was observed in the present study, but staining was absent in the nucleus 
(McCullough et al., 2013). To account for the potential artefactual staining which could 
confound the data, motoneuron GDNF levels were measured in only the cytoplasmic 
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compartment. The resulting trend remained unchanged, but the mean greyscale value of the 
exercised group was reduced from 136 to 123. This nuclear staining could be attributed to bleed 
through of the very bright DAPI staining of nuclei, as puncta within some nuclei align directly 




6.5 GDNF: Not sufficient to reduce astrocyte reactivity or cellular 
senescence 
Based on findings which have demonstrated that astrocytes play a role in the death of neurons 
observed with ageing and neurodegenerative disease via their senescent phenotype (Maragakis 
& Rothstein, 2006; Das & Svendsen, 2015; Rodríguez-Arellano et al., 2016), this study aimed 
to investigate whether this astrocyte senescence may be implicated in motoneuron death with 
age. GDNF has shown promising effects in reducing astrocyte reactivity and senescence (Zhao 
et al., 2004; Das & Svendsen, 2015), which in turn has benefits for motoneuron survival and 
viability. Combining the findings of each component of the current investigation, although 
exercise was able to significantly increase levels of GDNF within motoneurons of the lumbar 
Figure 31: Bright nuclear 
staining of ChAT and GDNF 
overlaid with DAPI staining 
Images of anti-Choline Acetyltransferase 
(ChAT) (A), anti-Glial-Derived 
Neurotrophic Factor (GDNF) (B) and DAPI 
staining (C) demonstrate that the bright 
regions align directly with the DAPI 
staining of the nuclei which appear white 




lateral motor column, this did not correlate with a reduction in GFAP levels, indicating that 
astrocyte reactivity was not reduced by the presence of GDNF. In addition to this, GDNF was 
not sufficient to reduce the presence of p16 positive nuclei within the lumbar lateral column. 
The ability of GDNF to act on astrocytes via its receptors GFR-α and RET depends on its ability 
to exit motoneuron cell bodies and exert its effects on astrocytes. The research which has 
described the protective effects of GDNF for astrocytic function has failed to demonstrate the 
mechanism for GDNF to act on astrocytes in vivo. One such study cultured astrocytes in GDNF; 
an approach which has countless limitations when comparing the mode of action of this trophic 
factor within whole tissues. There is no evidence to suggest the amount of GDNF administered 
is comparable to that circulating within the spinal cord, which makes it difficult to draw 
conclusions based on in vivo conditions.  
Further methods of investigating the relationship between GDNF and astrogliosis involved 
genetically overexpressing GDNF in skeletal muscle to demonstrate its effects on reducing 
astrogliosis and increasing astrocyte neuroprotection (Zhao et al., 2004; Li et al., 2007). Again, 
although these methods demonstrate the potential for GDNF as an exogenous treatment for 
diseases such as ALS and its benefits for motoneuron survival, they fail to address how in vivo, 
GDNF may act on astrocytes and implicate its protective benefits. In view of current findings, 
it may be concluded that this mechanism demonstrated in vitro is not translated in vivo, and that 
exercise-induced GDNF is unable to exert protective effects against astrocyte reactivity or 
cellular senescence with ageing. 
In summary, these results demonstrate that with ageing; GFAP showed a tendency to increase, 
p16 appears within cells which appear to be motoneurons, and GDNF showed no change. 
Exercise showed no effect on the expression of p16 or GFAP, but induced a large increase in 
GDNF levels within motoneurons. I believe these results demonstrate that astrocytes show a 
reduced neuroprotective capacity which may contribute to the death of motoneurons observed 
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with ageing. I also believe that the presence of p16 within motoneurons implicates their fate 
towards apoptosis, which contributes to loss of muscle mass and thus the progression of 
sarcopenia with age. (Fig. 32). 
 
  
Figure 32: Schematic demonstration of the findings of the current study 
This schematic summarises the findings of the current study. Skeletal muscle-derived Glial-Derived 
Neurotrophic Factor (GDNF) is taken up at the NMJ and exerts its effects directly on motoneurons to 
increase their survival and innervation of muscle fibers. Astrocytes show a reactive phenotype with age, 
but do not show markers of senescence: Instead, motoneurons show upregulated p16, which potentially 




6.6 Conclusions and future directions  
Here we report that astrocytes show an age-associated transition toward a more reactive state, 
indicating that they may show a reduced neuroprotective capacity of motoneurons, contributing 
to motoneuron death and subsequent loss of muscle mass with ageing. The dysfunction of 
astrocytes with ageing was not associated with expression of p16 which refutes my initial 
hypothesis that advancing age would trigger a senescent phenotype in astrocytes, and that this, 
in turn, might contribute to the loss of motoneurons and ultimately to sarcopenia. However, the 
surprising finding that p16 was probably elevated in motoneurons suggests that motoneurons 
themselves may be affected by p16 expression, in a manner that is not consistent with the 
senescent phenotype characterised in vitro. Instead, this p16 expression within motoneurons 
may be marking initiation of the apoptotic pathway (Ranganathan & Bowser, 2010), 
demonstrating that motoneurons are dying with age, driving the progression of sarcopenia. 
Exercise was investigated as it is a well-established intervention to slow the progression of 
sarcopenia via mechanisms which remain unknown. The current findings demonstrate that 
exercise was not able to reduce the reactive phenotype of astrocytes or the appearance of p16-
positive nuclei within the lumbar lateral motor column. Exercise was able to induce a large 
increase in GDNF levels within spinal motoneurons, which likely increases motoneuron 
survival, number of motor units, innervation at the NMJ, and motor function, as previously 
reported (Li et al., 2007; Park & Höke, 2014). It would also be useful to include analysis of 
parallel changes in neuromuscular status as a result of change in GDNF levels to evaluate the 
direct benefits of this trophic factor for motoneurons. 
It has become apparent during the course of the study that senescence is a very broad term with 
complex roles and implications in living systems. Future work needs to identify the p16 positive 
cells present, and to measure other markers of the SASP such as IL-6, IL-8 and TNF-α to 
evaluate changes in neuroinflammation and whether these are attributable to the presence of 
p16-positive cells. Based on the findings which implicate the p16-Rb-E2F pathway of 
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senescence induction in apoptosis, it would be useful to co-stain p16 with apoptotic markers 
such as TUNEL and caspase-3, to determine if p16 expression precedes motoneuron death - a 
driver for sarcopenia. 
Investigations into mechanisms of sarcopenia have traditionally focused on the muscle where 
changes are visibly occurring. The direct effects of age could manifest in the muscle, but if cells 
higher up the chain of command were directly affected, then muscle would surely be impacted 
as a secondary consequence - such as is observed following the death of motoneurons causing 
disuse atrophy of orphaned muscle fibers. By understanding that the neuromuscular system 
consists of a chain of command, and that each component in the chain is necessary to allow 
maintenance of muscle mass, we can see the diverse nature of the cells involved in maintaining 
this system.  
In this work I have begun to investigate the extent to which changes in the nervous system 
might impact on muscles, and thereby to evaluate the contribution of non-muscle tissues to 
sarcopenia. Although my hypotheses were not fully supported by my data, I have described 
interesting changes in important intercellular signalling factors and processes that potentially 
point to new avenues to explore for a better understanding of the neuromuscular changes that 
occur with advancing age. Only when we know why the nervous system and the skeletal 
muscles undergo age-related degenerative change will be in a position to prevent or delay those 
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Appendix A: Recipes for immunohistochemistry 
 
Table 4: 20X Tris-Buffered Saline (TBS)* 
 
Component Amount 
Tris Xtrapure 1220g 
NaCl 1800g 
Hydrochloric acid (37%) pH 7.4 
Distilled water 10L 
*To make 1L of 1x, add 50mL of 20x to 950L distilled water. 
*To make 1L of 2x, add 100mL of 20x to 900mL distilled water. 
 












BSA (1%) 100mL 
TritonX-100 (0.1%) 10mL 
Tween20 (0.3%) 30mL 
Distilled water 860mL 
pH balanced 7.3 
Component Amount 
Tri-sodium citrate 2.94g 
Distilled water 1L 
Twen20 0.5mL 























Table 11: Sucrose (20%) for cryoprotection 
Component Amount 
Tris Xtrapure 1.3g 
Distilled water 1L 
Tween20 0.5mL 
NaOH  pH 10 
Component Amount 





Distilled water 200mL 
Component Amount 
Paraformaldehyde 1g 
NaH2PO4 (0.2M) 11mL 
Na2HPO4 (0.2M) 39mL 













Sodium Dodecyl Sulphate 0.3g 





Distilled water 100mL 
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Appendix B: Western blot recipes 
 
Table 13: 10x TBST* 
*To make 1L of 1x, add 100mL of 10x to 900mL of distilled water. 
 
Table 14: 10x Running buffer* 
*To make 1L of 1x, add 100mL of 10x running buffer to 900mL distilled water. 
 










Tween20 (0.5%) 5mL 
pH balanced 7.6 
Component Amount 
Glycine (1.92M) 144g 
Tris (0.25M) 30.2g 
Sodium dodecyl sulfate (SDS) (1%) 10g 
Component Amount 
Glycine (1.92M) 14.4g 
Tris (0.25M) 3.02g 
Distilled water 800mL 
Methanol 200mL 










Table 17: Loading samples (20μg protein) 
Sample For 20μg protein (μl) Sample buffer (μl) Distilled water (μl) 
1 3.4 4 12.6 
2 4.5 4 11.5 
3 5.1 4 10.9 
4 6.0 4 10.0 
5 5.3 4 10.7 
6 3.8 4 12.2 
7 5.7 4 10.3 
8 4.5 4 11.5 
9 3.8 4 12.2 
10 4.5 4 11.5 
  
Component Amount 
Lower tris 2mL 
Glycerol 5mL 
SDS (10%) 1g 
Dithiothreitol (DTT) (0.2M) 0.31g 
10% SDS 1mL 
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Figure 33: Transcardial perfusion 
A) Following anaesthetisation, toes were pinched with forceps to ensure deep anaesthesia was achieved. 
B) Skin and connective tissue bluntly dissected to expose the ribcage. C) The ribcage was cut twice, once 
toward each axilla. D) The ribcage was deflected to expose the heart and a needle attached to a 
peristaltic pump was inserted into the left ventricle. E) The right atrium was cut to allow blood and 




Spinal cord removal 
 
  
Figure 34: Spinal cord removal 
A) The mouse was orientated with the legs facing away. B) The skin and connective tissue was 
bluntly dissected to expose the underlying abdominal cavity. C) The visceral organs were 
removed. D) Incisions were made through the ventral spinous processes to expose the central 
canal and allow excision of the cord in a rostral to caudal direction. E) The cord was exposed 
until the cauda equina was reached. F) The removed cord was placed in 1xTBS on ice. 
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Appendix D: Semi-Quantitative Immunohistochemistry (SQI) validation 
  
Figure 35: Linear relationship between protein amount and greyscale value. 
A reference standard was generated using agarose with known amounts of protein suspended 
within. The agarose was treated with antibodies and imaged using the fluorescence microscope and 
average greyscale value was measured. 
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